Document:

Amendment No.2 to Assignment Agreement

 [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange
Commission. Confidential treatment has been requested with respect to the omitted portions. 
 EXHIBIT 10.1 
 AMENDMENT NO. 2 
 to 

ASSIGNMENT AGREEMENT 
 This
AMENDMENT TO ASSIGNMENT AGREEMENT (“Amendment”), effective as of March 2, 2009 (the “Amendment Date”), is made and entered into by and between PHARMACYCLICS, INC., a Delaware corporation having a
place of business at 995 East Arques Avenue, Sunnyvale, California 94085, (“Pharmacyclics”) and CELERA CORPORATION having a place of business at 1401 Harbor Bay Parkway, Alameda, California 94502 (“Celera”).
Pharmacyclics and Celera may each be referred to herein individually as a “Party” or, collectively, as “Parties.” 
 WHEREAS, Applera Corporation, through its Celera Group, entered into an assignment agreement with Pharmacyclics, effective as of April 7, 2006, whereby the Celera Group assigned to Pharmacyclics certain proprietary technology
and know-how related to the Celera Programs, including but not limited to the HDAC Program (the “Original Assignment Agreement”); 
 WHEREAS, Pharmacyclics and the Applera Corporation, through its Celera Group, subsequently executed Amendment No. 1 to the Original Assignment Agreement, effective May 12, 2008, in order to amend certain payment terms of
the Assignment Agreement relating to [***] (the “First Amendment”) (the Original Assignment Agreement, as amended by the First Amendment, hereinafter the “Assignment Agreement”); 
 WHEREAS, The Celera Group was spun out of the Applera Corporation in July 2008 to create the Celera Corporation, and the Assignment Agreement was
assigned by the Applera Corporation to the newly formed Celera Corporation; 
 WHEREAS, Pharmacyclics desires that certain terms of
the Assignment Agreement should be amended; and 
 WHEREAS, Celera desires that such terms should be amended, subject to the terms and
conditions set forth below 
 NOW, THEREFORE, in consideration of the mutual covenants and obligations set forth herein, and for other
good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Pharmacyclics and Celera hereby agree as follows: 
  

	1.	In General. 

 All terms defined in the Assignment
Agreement shall have a meaning in this Amendment as in the Assignment Agreement, unless otherwise expressly defined in this Amendment. 
  

	2.	Amendment of the Assignment Agreement. 

 2.1 Amendment of first sentence of Section 6.3(a). The first sentence of Section 6.3(a)
of the Assignment Agreement is hereby amended to read as follows: 
 Pharmacyclics will pay to Celera payments as set forth in this
Section 6.3 within sixty (60) days after (i) under Section 6.3(b) and 6.3(c), Pharmacyclics’ receipt of upfront and milestone payments from one or more Licensees upon the grant by Pharmacyclics of a license to such Licensee
under the Celera Technology and the Celera Patents to make, use, offer to sell, sell and import any Assigned Product which is an [***], and (ii) under Section 6.3(d), the first achievement of the corresponding milestone for an
Assigned Product which is an [***] or which is a [***]. 
 2.2 Amendment of Section 6.3(d). In the event that
Pharmacyclics and [***] (“[***]”) enter into an agreement within [***] ([***]) days of the Amendment Date pursuant to which Pharmacyclics grants to [***] a license to make, use, offer to sell, sell and
import one or more [***] (“[***] License Agreement”), then Section 6.3(d) of the Assignment Agreement shall be, and hereby is, amended as follows: 
 The Milestone Payment due for an [***] upon achievement of Milestone 1 (“Administration of an Assigned Product to the first
patient in a Phase 3 Clinical Trial”) is reduced to [***]Dollars ($[***]); 
 A new Milestone Payment
applicable to an [***] (Milestone 1A), in the amount of [***]Dollars ($[***]), will be due upon enrollment of the last subject in the Phase 3 Clinical Trial. 
 The Milestone Payments due for an [***]upon achievement of Milestone 6 (“Regulatory Approval in [***] of an NDA for an
Assigned Product for a second indication”) and Milestone 7 (“Regulatory Approval in [***] of an NDA for an Assigned Product for a second indication”) are hereby eliminated. 
 A new Milestone Payment (Milestone 1B), in the amount of [***]Dollars ($[***]), will be due upon achieving cumulative Net
Sales in the [***]of [***]Dollars ($[***]) of an [***]. 
 2.3 Addition of New Section 6.3(e). A new
Section 6.3(e) reading in its entirety as follows is hereby added to the Assignment Agreement: 
 (e) Subject to
the terms and conditions of this Agreement, in the event that Pharmacyclics, having granted a license to a Licensee as contemplated in Section 6.3(b) or 6.3(c), grants a second license to a Licensee under the Celera Technology and the Celera
Patents to make, use, offer to sell, sell and import any [***], the Parties agree that in exchange for Pharmacyclics paying to Celera the greater of (i) [***] ([***]%) of the amount received by Pharmacyclics as an upfront
payment from such Licensee, or (ii) [***] Dollars ($[***]), the Milestone Payment due upon achievement of Milestone 5 (“Regulatory Approval in [***] of an NDA for an Assigned Product for a second indication”) in
Section 6.3(d) above shall be reduced to [***] Dollars ($[***]). For purposes of this Section 6.3(e), the term “upfront payment” does not include amounts reasonably and fairly attributable to bona fide (i) debt
financing, (ii) sale of equity in 

  

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
Pharmacyclics, (iii) reimbursement for the cost and expense of research, development, clinical services, and/or pre-marketing activities incurred by
Pharmacyclics after the effective date of such license and attributable to [***], or (iv) reimbursement of patent filing, prosecution and maintenance expenses incurred by Pharmacyclics and attributable to [***]. 
 2.4 Amendment of Sections 6.4(a) and (b). In the event that Pharmacyclics and [***] within [***] ([***]) days of the
Amendment Date, then Sections 6.4(a) and (b) of the Assignment Agreement shall be, and hereby are, amended to read in their entirety as follows: 
 (a) Subject to the terms and conditions of this Agreement, Pharmacyclics will pay Celera a tiered Royalty on Net Sales of [***] and [***] in accordance with the following table: 
  

					
	 Total Net Sales of an Assigned
 Product in a Calendar Year
	  	 Percent of Net Sales

		  	[***]    	  	[***]    
	 [***] to $ [***]
	  	[***]%	  	[***]%
	 $ [***] to $ [***]
	  	[***]%	  	[***]%
	 Above $ [***]
	  	[***]%	  	[***]%

 (b) Subject to the terms and conditions of this Agreement, Pharmacyclics
will pay Celera a Royalty on Net Sales of [***] in accordance with the following table based on the country of sale: 
  

			
	 Territory
	  	Royalty Rate
	 [***]
	  	[***]%
	 [***]
	  	[***]%

 2.5 Amendment of Section 6.5(a). Section 6.5(a) of the Assignment Agreement is
hereby amended to read in its entirety as follows: 
 (a) In the case of any Assigned Product described in
Section 1.5, Section 1.28 (except in the case of Assigned Products described in Section 1.28(b)(iii)) and Section 1.35 (except in the case of Assigned Products described in Section 1.35(b)(iii)), for as long as the
manufacture, use, sale, offer for sale or import of such Assigned Product is covered by a Celera Patent in the country in which such Assigned Product is used or sold. 
  

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 2.6 Amendment of the last sentence in Section 7.1. The last sentence in Section 7.1 of
the Assignment Agreement is hereby amended to read as follows: 
 Celera will not enforce any Reverted Patent against Pharmacyclics or any
Assigned Product(s) as long as Celera is receiving a royalty payment under Section 6.4 of this Agreement with respect to any Assigned Product within the scope of such Reverted Patent. 
 2.7 Amendment of the first sentence of Section 7.2(a). The first sentence of Section 7.2(a) of the Assignment Agreement is hereby
amended to read as follows: 
 Pharmacyclics has the sole right (itself or through its designees) to enforce the Celera Patents against Third
Parties and to defend the Celera Patents against any challenge. 
 2.8 Amendment of the fifth sentence of Section 10.3. The fifth
sentence of Section 10.3 of the Assignment Agreement is hereby amended to read as follows: 
 Either Party may disclose the terms of this
Agreement to potential investors, accountants, attorneys and others on a need-to-know-basis, who agree to be bound by obligations of non-disclosure and non-use at least as stringent as those contained in this Article 10. 
 2.9 Addition of New Section 11.2. A new Section 11.2 reading in its entirety as follows is hereby added to the Assignment Agreement:

 11.2 Termination by Pharmacyclics. Any provision herein notwithstanding, Pharmacyclics may terminate this Agreement,
in its entirety or with respect to one or more of the three classes of products acquired from Celera under this Agreement (i.e., [***],[***], and [***]; each such class of products a “Product Class”), at any time by
giving Celera at least [***] ([***]) days prior written notice. From and after the effective date of a termination under this Section 11.2 with respect to a particular Product Class, the products within such terminated Product
Class will cease to be Assigned Products and ownership of all Celera Intellectual Property directed to such terminated Product Class shall revert to Celera as provided in Section 11.4 below. Upon a termination of this Agreement in its entirety
under this Section 11.2, the ownership of all Celera Intellectual Property shall revert to Celera as provided in Section 11.4 below the all rights and obligations of the parties shall terminate, except as provided in Section 11.5
below. Notwithstanding the foregoing, Pharmacyclics agrees that the royalty and milestone obligations under Sections 6.3 and 6.4 with respect to any Assigned Products of the type described in Section 1.28(b)(iii) and Section 1.35(b)(iii)
that are in existence as of the effective date of such termination shall continue in full force and effect for the period specified in Section 6.5(b). 
 2.10 Amendment of Former Section 11.2. Former Section 11.2 of the Assignment Agreement is hereby relabeled as Section 11.3 and amended to read in its entirety as follows: 
 11.3 Termination for Default. Subject to Section 12.1 below, this Agreement may be terminated effective immediately by written
notice by either Party at any time during the Term for Default by the other Party, which Default remains uncured for [***]  

  

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
([***]) days, measured from the date written notice of such Default is given to the Defaulting Party (“Cure Period”), provided,
however, that if such Default is not susceptible of cure within the stated Cure Period and the Defaulting Party uses diligent good faith efforts to cure such Default, the stated period will be extended by an additional [***]
([***]) days. Notwithstanding the foregoing, to the extent a given Default by Pharmacyclics relates primarily to one or two (but not all three) Product Classes (e.g., a breach by Pharmacyclics of its obligations under Section 3.2,
3.4, 5.2, 5.3 or 8.4(b) with respect to a particular Product Class), then to the extent that Celera would be entitled to a terminate this Agreement under the preceding terms of this Section 11.3, such right of termination shall be limited to
the Product Class(es) which are the subject of such Default and shall not apply to any Product Class(es) that are not the subject of such Default. 
 2.11 Amendment of Former Section 11.3. Former Section 11.3 of the Assignment Agreement is hereby relabeled as Section 11.4 and amended to read in its entirety as follows: 
 11.4 Reversion. In the event of an early termination of this Agreement (i.e., a termination of this Agreement before expiration of
the Term) the following shall apply: 
 (a) In the event of an early termination of this Agreement with respect to a
particular Product Class, Pharmacyclics will, subject to Section 11.4(c) below, assign to Celera all right, title and interest in and to all Celera Intellectual Property directed to such terminated Product Class. 
 (b) In the event of an early termination of this Agreement in its entirety, Pharmacyclics will, subject to Section 11.4(c)
below, assign to Celera all right, title and interest in and to all Celera Intellectual Property. 
 (c) Celera and
Pharmacyclics hereby agree that to the extent that Pharmacyclics has granted one or more licenses under the Celera Intellectual Property prior to such early termination, the assignment of the Celera Intellectual Property contemplated in Sections
11.4(a) and 11.4(b) above shall be subject to such licenses and shall not alter or diminish any Licensee’s rights with respect to such license(s). For clarity, the Parties agree that each Licensee’s license shall survive if the relevant
Licensee agrees in writing to be bound by the applicable terms of this Agreement (i.e., the applicable royalty, milestone payment and other financial terms of this Agreement). Additionally, any Licensee with a surviving license under the Celera
Intellectual Property agrees that upon Celera’s request, Celera and such Licensee shall formalize such surviving license by executing a direct license under the Celera Intellectual Property, which direct license shall be of the same scope as
Licensee’s license from Pharmacyclics and shall contain substantially identical terms and conditions (including the same financial and other terms) as those contained in this Agreement. For clarity it is understood and agreed that
(i) Pharmacyclics will remain responsible for any and all payments and other obligations accruing to Celera under the this Agreement prior to termination of this Agreement and that each Licensee shall only be responsible for any payments that
become due as a result of such Licensee’s activities after the effective date of any such termination, (ii) that Licensees will not be responsible for any milestone payments already paid by Pharmacyclics prior to the effective date of any
such 

  

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
termination, and (iii) notwithstanding anything to the contrary in this Section 11.4(c), only those products existing as of the effective date of
the termination of this Agreement and which are the subject of Licensee’s license from Pharmacyclics will be considered “Assigned Products” for purposes of Licensee’s surviving license. 
 2.12 Amendment of Former Section 11.4. Former Section 11.4 of the Assignment Agreement is hereby relabeled as Section 11.5 and
amended to read in its entirety as follows: 
 11.5 Survival. The following provisions will survive any expiration or
termination of this Agreement for the period of time specified: Articles 1, 9, 10, 12 and 13, and Sections 8.6, 11.4 and 11.5. Additionally, as described in Section 11.4(c) above, Pharmacyclics royalty and milestone payment
obligations under Sections 6.3 and 6.4 with respect to any then existing Assigned Products of the type described in Section 1.28(b)(iii) and Section 1.35(b)(iii) shall survive for the period specified in Section 6.5(b). Termination of
this Agreement will not relieve the Parties of any liability which accrued hereunder prior to the effective date of such termination nor preclude either Party from pursuing all rights and remedies it may have hereunder or at law or in equity with
respect to any breach of this Agreement nor prejudice either Party’s right to obtain performance of any obligation. The remedies provided in this Article 11 are not exclusive of any other remedies a Party may have in law or equity.

 2.13 Amendment of Section 12.1. Section 12.1 of the Assignment Agreement is hereby amended to read in its entirety as
follows: 
 12.1 Disputes. 
 (a) The Parties recognize that disputes as to certain matters may from time to time arise during the Term which relate to either
Party’s rights or obligations hereunder. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes arising from, concerning or in any way relating to this Agreement in an expedient manner by mutual
cooperation and without resort to litigation. To accomplish this objective, the Parties agree to follow the procedures set forth in this Section 12.1 if and when a dispute arises under this Agreement. The Parties will undertake good faith
efforts to resolve any such dispute in good faith. In the event the Parties are unable to resolve such dispute, either Party may, by written notice to the other Party, have any dispute between the Parties remaining unresolved after thirty
(30) days referred to their respective executive officers designated below or their designees or successors for attempted resolution by good faith negotiations within thirty (30) days after such notice is received. Such designated officers
are as follows: 
  

			
	 	  	For Pharmacyclics: Chief Executive Officer
		
	 	  	For Celera: Chief Executive Officer

 (b) If the designated officers are not able to resolve such dispute within
such thirty (30) day period, either Party may at any time thereafter refer such dispute (unless relating to intellectual property, in which case such dispute shall be subject to the terms of Section 12.3 below) to final, binding
arbitration in accordance 

  

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 
with the provisions of this Section 12.1. The arbitration shall be conducted by the Judicial Arbitration and Mediation Services, Inc. (or any successor
entity thereto) (“JAMS”) under its rules of arbitration then in effect, except as modified in this Agreement. The arbitration shall be conducted in the English language, by a single arbitrator, who shall use all reasonable efforts to
complete such arbitration within six (6) months from the date of referral of such dispute to arbitration. The arbitrator shall determine what discovery will be permitted, consistent with the goal of limiting the cost and time which the Parties
must expend for discovery; provided that the arbitrator shall permit such discovery as he or she deems necessary to permit an equitable resolution of the dispute. Unless otherwise mutually agreed upon by the Parties, the arbitration proceedings
shall be conducted in San Jose, California. The Parties agree that they shall share equally the cost of the arbitration filing, hearing fees and the cost of the arbitrator and administrative fees of JAMS. Each Party shall bear its own costs and
attorneys’ and witnesses’ fees and associated costs and expenses. 
 (c) The Parties agree that the decision
of the arbitrator shall be the sole, exclusive and binding remedy between them regarding the dispute presented to the arbitrator. Any decision of the arbitrator may be entered in a court of competent jurisdiction for judicial recognition of the
decision and an order of enforcement. The arbitration proceedings and the decision of the arbitrator shall not be made public without the joint consent of the Parties and each Party shall maintain the confidentiality of such proceedings and decision
unless each Party otherwise agrees in writing; provided that either Party may make such disclosures as are permitted for Confidential Information of the other Party under Article 10 above. 
 (d) Pending the selection of the arbitrator or pending the arbitrator’s determination of the merits of any dispute, either
Party may seek appropriate interim or provisional relief from any court of competent jurisdiction as necessary to protect the rights or property of that Party. In addition, notwithstanding Section 11.3 above, if a Party alleged to be in Default
disputes such Default within the Cure Period specified in Section 11.3, this Agreement shall not be terminated unless an arbitrator determines in a written decision delivered to the Parties under this Section 12.1 that this Agreement was
materially breached, and the breaching Party fails to cure such breach within ninety (90) days after such determination, or if not curable during such period, within a reasonable period to be determined by the arbitrator. 
 2.14 Amendment to delete the last sentence of Section 12.2. The last sentence of Section 12.2 of the Assignment
Agreement reading “The exclusive jurisdiction for any dispute arising under this Agreement will be a state or federal court of competent jurisdiction in California.” is hereby deleted. 
  

	3.	Reference to and Effect on the Assignment Agreement. 

 3.1 Pursuant to Section 13.1 of the Assignment Agreement, this Amendment shall be effective upon the Amendment Date, whereupon the Assignment Agreement shall be, and hereby is, amended as set forth herein.

  

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 3.2 On and after the Amendment Date, each reference in the Assignment Agreement to
“this Agreement,” “hereunder,” “hereof,” “herein” or words of like import shall mean and be a reference to the Assignment Agreement as amended hereby. No reference to this Amendment need be made in any
instrument or document at any time referring to the Assignment Agreement, a reference to the Assignment Agreement in any of such to be deemed to be a reference to the Assignment Agreement as amended hereby. 
 3.3 All provisions of the Assignment Agreement not expressly modified by this Amendment shall remain in full force and effect.

  

	4.	Counterparts. 

 This Amendment may be executed in
one or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute a single instrument. 
 IN WITNESS THEREOF, the Parties have caused this Amendment to be duly executed by their respective duly authorized officers as of the Amendment Date. 
  

									
	 PHARMACYCLICS, INC.
 (“Pharmacyclics”)
	 		 	 CELERA CORPORATION
 (“Celera”)

					
	By:	 	/s/ Robert Duggan	 		 	By:	 	/s/ Stacey Sias
					
	Print Name:	 	Robert Duggan	 		 	Print Name:	 	Stacey Sias
					
	Title:	 	CEO & Chairman	 		 	Title:	 	VP & Chief Business Officer

  
  
  

 [***] Certain information in this document has been omitted and filed separately with the Securities and
Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.Amended and Restated Manufacturing Technology Transfer and Supply Agreement

 Exhibit 10.1 
 Confidential 
 AMENDED AND RESTATED MANUFACTURING TECHNOLOGY TRANSFER AND 
 SUPPLY AGREEMENT 
 BY AND BETWEEN

 ANTIGENICS, INC., A MASSACHUSETTS CORPORATION 
 AND 
 GLAXOSMITHKLINE BIOLOGICALS SA 

 Confidential 
  

 AMENDED AND RESTATED MANUFACTURING TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT 
 This Amended and Restated Manufacturing Technology Transfer and Supply Agreement (this “Agreement”) is made effective this 16th day of
January, 2009 (“Effective Date”) by and between Antigenics Inc., a Massachusetts corporation and wholly owned subsidiary of Antigenics Inc., a Delaware corporation, having offices at 3 Forbes Road, Lexington, MA 02421
(“Antigenics MA”), and GlaxoSmithKline Biologicals SA, a Belgian company, having an address at 89 rue de l’Institut, 1330 Rixensart, Belgium (“GSK”) (each singularly a “Party” and collectively
the “Parties”). 
 WHEREAS, Antigenics MA and GSK were parties to that certain License, Development, and Supply Agreement
entered into effective September 11, 1992 between Cambridge Biotech Corporation (predecessor to Antigenics MA) and Smithkline Beecham p.l.c. (predecessor to GlaxoSmithKline plc an Affiliate of GSK) (as amended, the “1992
Agreement”); and 
 WHEREAS Antigenics MA and GSK terminated and superceeded the 1992 Agreement with that certain Manufacturing
Technology Transfer and Supply Agreement entered into effective July 6, 2006 between the Parties (the “2006 Supply Agreement”) and the License Agreement (as defined below); 
 WHEREAS, the Parties entered into that certain Binding Letter of Intent dated July 20, 2007 (the “Letter”) to accelerate GSK’s
manufacturing rights for QS-21 under the 2006 Supply Agreement; and 
 WHEREAS, GSK and Antigenics MA now desire to memorialize their
understanding as described in the Letter and supercede and amend and restate the 2006 Supply Agreement with this Agreement; 
 NOW,
THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties do hereby agree as
follows: 
 1. Definitions. 
 The following
terms, whether used in the singular or the plural, shall have the following meanings for purposes of this Agreement: 
 1.1
Affiliate” means any corporation, firm, partnership or other entity, which controls, is controlled by or is under common control with a Party. For purposes of this Section 1.1, “control” means direct or indirect ownership
of fifty percent (50%) or more, or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction, of the outstanding stock or other voting rights entitled to elect directors thereof or the
ability to otherwise control the management of the corporation, firm, partnership or other entity. 
  

 1 

 Confidential 
  

 1.2 “BMF” means (a) Antigenics MA’s FDA biologics master
file(s) for QS-21 and (b) GSK’s and/or its Affiliate’s and/or [**] biological master file(s) for QS-21, existing now or at any time in the future, as the case may be. 
 1.3 “Business Day” means a day on which banking institutions in both Brussels, Belgium and Boston, Massachusetts are open
for business. 
 1.4 “cGMP” means the current European Guidelines, ICH Guidelines and United States Good
Manufacturing Practices for Finished Pharmaceuticals pursuant to 21 C.F.R. 210 et seq., as amended from time to time. 
 1.5
“cGMP Consistency Lots” means minimum of [**] commercial grade process validation runs for Antigenics MA’s facility, Manufactured in accordance with the Specifications. 
 1.6 “Completion of the Transfer of the Manufacturing Technology Package” means (a) transfer of all documents of the
Manufacturing Technology Package by Antigenics MA to GSK and (b) performance of a [**] in accordance with [**] and [**] of [**] at [**] in accordance with [**] and [**] of [**] at [**], of one (1) [**] of [**] (which [**] is [**] without
any [**] from the [**] which would [**] and [**]), in accordance with the Manufacturing Technology Transfer Plan, which [**] shall be [**] the [**] to [**] in [**] with [**], for the [**] of [**] and [**] the transfer of the Manufacturing Technology
Package. For avoidance of doubt, Completion of the Transfer of the Manufacturing Technology Package does not require [**] and [**] of [**]. 
 1.7 “Confidential Information” has the meaning set forth in Article 9 hereof. 
 1.8 “Customer” means (a) Antigenics MA, in the case where GSK is Manufacturing and supplying for Antigenics MA hereunder, or (b) GSK, in the case where Antigenics MA is Manufacturing and supplying for GSK
hereunder. 
 1.9 “FDA” means the United States Food and Drug Administration or any successor entity thereto.

 1.10 “First Commercial Sale” means the date of first commercial sale of a QS-21 Vaccine by GSK or its
Affiliates or Third Party Sublicensees or distributors anywhere in the Territory. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 2 

 Confidential 
  

 1.11 “Fully Burdened Costs” means: (a) in the case where [**]
Manufactures QS-21 for supply to [**] hereunder, the total cost to Manufacture by [**] and/or its Affiliates hereunder, which total cost shall include direct and indirect labor costs, direct material costs (including without limitation, raw
materials, lab supplies and other materials used directly in Manufacturing QS-21) and indirect material costs (including without limitation shipping materials (driven by shipments not batches), stability materials, batch record materials, sundry
supplies to support QS-21 Manufacture, record keeping, stationary, incidental supplies etc.) calculated in accordance with Generally Accepted Accounting Principles (“GAAP”), and Other Overhead Costs calculated in accordance with GAAP [**];
or (b) in the case where [**] engages a Third Party to Manufacture QS-21 on its behalf for supply to [**] hereunder, the actual cost to [**] to have QS-21 Manufactured and supplied by such Third Party, including without limitation, direct and
indirect costs borne by [**] for any internal quality assurance, quality control, fill/finish, packaging, shipping, and/or delivery, in each case as duly documented by [**]. In the case [**] is [**]of the [**] (both [**] and [**]) to meet it supply
obligations under this Agreement, the [**] of the [**] shall be added to the [**]to [**] and/or the [**]by [**] as appropriate, however, in no event shall any [**] be included as part of the Fully Burdened Costs. [**] In the event that [**]
Manufactures QS-21 for [**] and/or other customers of [**] during this period, [**] and these other customers will bear their appropriate proportionate share of the [**]. For the avoidance of doubt, in no event shall any of the cost components
exclusive of the Manufacturing direct labor and direct material costs exceed [**]. 
 For either (a) or (b) above, Fully Burdened Costs shall also
include direct and indirect costs incurred by [**] as a result of [**] fulfilling its Manufacturing and supply obligations pursuant to this Agreement, but shall specifically exclude any costs or expenses otherwise payable or reimbursable by [**]
hereunder, if applicable. Upon [**] by [**] to [**],[**] estimated Fully Burdened Cost details shall be updated annually (or semi-annually upon the request of Customer) by Supplier and shall be [**]. 
 1.12 “Gross Sales” has the meaning set forth in Section 1.26 below. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 3 

 Confidential 
  

 1.13 “GSK Capacity Date” means the date upon which GSK has
commercial grade QS-21 Manufacturing capabilities such that it is capable of supplying Antigenics MA with QS-21 in accordance with this Agreement, but in no event later than [*]. 
 1.14 “Letter” has the meaning set forth in the third Whereas clause. 
 1.15 “License Agreement” means the license agreement by and between Antigenics MA and GSK entered into contemporaneously
with the 2006 Supply Agreement and providing GSK with license rights under certain intellectual property to use QS-21 (as defined below) to develop, make, have made, use, sell, offer for sale and import certain products containing QS-21. 

1.16 “Licensed Indications” means the Vaccine indications licensed to GSK pursuant to the License Agreement.

 1.17 “Licensed Vaccines” means the Vaccines for which GSK has license rights under the License Agreement.

 1.18 “Manufacture or Manufacturing” means the storage, production, purification, handling, materials
procurement, processing, testing, packaging and release of QS-21 in accordance with this Agreement. 
 1.19
“Manufacturing Capacity” means (a) in the case where Antigenics MA is the Supplier, the amounts of QS-21 binding on GSK as set forth on Exhibit B attached hereto and incorporated herein, or such higher capacity as
Antigenics MA may advise GSKin accordance with Exhibit B, and (b) in the case where GSK is the Supplier, [**] of QS-21 per [**], provided that in the event that Antigenics MA requests more than [**] of QS-21 per [**], GSK will
reasonably consider any such requests for increased capacity, such agreement not to be unreasonably withheld if it would not interfere with GSK’s own QS-21 supply needs. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 4 

 Confidential 
  

 1.20 “Manufacturing Improvements” means any development,
enhancement, improvement, invention, modification, or derivative (whether or not patentable) necessary for or actually applied to the Manufacture of QS-21 that is made, discovered, conceived or reduced to practice by or on behalf of GSK or its
Affiliates in the course of the further development or Manufacturing of QS-21 at any time during the term of the [**], or the [**] of this Agreement or by Antigenics MA or its Affiliates in the course of the further development or Manufacture of
QS-21 at any time during the term of the [**], or the [**] of this Agreement. For the avoidance of doubt, Manufacturing Improvements specifically exclude any development, enhancement, improvement, invention, modification, or derivative (whether or
not patentable) relating to [**] (as opposed to [**]) or [**] or [**] or [**] of [**] with a [**] other [**] or any other [**] of a [**]. 
 1.21 “Manufacturing Technology” means (i) United States Patent No. [**] (the “‘[**] Patent”), together with any patents issuing from any continuations, continuations-in-part (to
the extent that the claims therein are directed to subject matter disclosed in the ‘[**] Patent), divisionals, substitutions, reissues, reexaminations or extensions of the ‘[**] Patent, and any foreign counterparts or equivalents of the
foregoing, and (ii) the technical and regulatory information contained in the Manufacturing Technology Package, and (iii) any know-how owned or controlled by Antigenics MA (with the right to grant licenses or sublicenses hereunder)
existing as of the effective date of the 2006 Supply Agreement that are necessary or reasonably useful for the Manufacture of QS-21 and (iv) any Manufacturing Improvements owned or controlled by Antigenics MA or its Affiliates (with the right
to grant licenses or sublicenses hereunder) whether or not claimed by a patent filed by Antigenics MA. 
 1.22
“Manufacturing Technology Package” means all relevant technical and regulatory information on QS-21 and the QS-21 Manufacturing process owned and/or controlled by Antigenics MA (with the right to transfer to GSK BIO), as listed
under the heading “Phase 1: Transfer of Enabling Technology (Manufacturing Technology Package)” in the Manufacturing Technology Transfer Plan. 
 1.23 “Manufacturing Technology Transfer Royalty” has the meaning set forth in Section 5.3 hereof. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 5 

 Confidential 
  

 1.24 “Manufacturing Technology Transfer Plan” means the written
transfer plan agreed to between the Parties pursuant to the 2006 Supply Agreement and to be updated by mutual written agreement of the Parties within a reasonable time after execution of this Agreement, which forms an integral part hereof, which
will set forth the activities of each Party relating to the objectives, criteria, milestones and timelines relating to each Party’s Manufacturing activities hereunder including without limitation, cooperation of the Parties to ensure [**]
between the Parties and timelines for [**] of QS-21 as further described therein, and as may be updated from time to time until completion of all contemplated activities. 
 1.25 “Marketing Approval” means approval received from the FDA or any comparable approval in any non-US jurisdiction with
any relevant Regulatory Authority granting the right to commercialize QS-21 Vaccines (but specifically independent of pricing or reimbursement considerations, where applicable). 
 1.26 “Net Sales” means the amount billed or invoiced on arms length sales of QS-21 Vaccines by GSK, its Affiliates or
Third Party Sublicensees to Third Parties including its distributors (“Gross Sales”) less deductions duly documented for (i) normal and customary trade, quantity and cash discounts and non-affiliated broker’s,
distributor’s or agent’s commissions actually allowed and taken; (ii) amounts repaid or credited by reason of rejection or return or retroactive price reduction; (iii) to the extent separately stated on purchase or sales orders,
invoices, or other documents of sale, sales and excise taxes and duties levied on and/or other governmental charges made as to production, sale, importation, transportation, delivery or use paid by or on behalf of GSK or its Affiliates or Third
Party Sublicensees; (iv) transportation costs including insurance; and (v) the [**] determined as [**] of [**] and other special [**] and/or [**] and [**] with Licensed Vaccines; (vi) any [**] to [**] on [**], provided however that
deductions under this subparagraph (vi) shall not exceed [**] of [**]; and (vii) contributions and payments required by the United States Government to be made pursuant to the [**], specifically with respect to any of [**], and which [**]
and [**] have been [**] on to the [**] and are [**] in the [**] of [**] and which are not [**], provided however that deductions under this subparagraph (vii) and subparagraph (v) shall not exceed [**] of [**] in the [**]. Sales between or
among GSK and its Affiliates or Third Party Sublicensees shall be excluded from the computation of Net Sales except where the Affiliates or Third Party Sublicensees are end users, but Net Sales shall include the subsequent final sales to Third
Parties by the Affiliates or Third Party Sublicensees. 
 For the avoidance of doubt, in the event GSK gets any indirect financial interest, income or other
consideration back from the subsequent QS-21 Vaccines sales of GSK distributors to Third Parties, such financial interest, income or consideration shall be included as Net Sales. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 6 

 Confidential 
  

 In addition, in the event that GSK has entered into a distribution agreement with a Third Party and which
distribution agreement is in a form that is in economic and business substance a sublicense relationship and not a traditional distribution relationship in such country or countries, then such distributor shall be treated as a Sublicensee for
purposes of calculating Net Sales and royalties hereunder. 
 If GSK or any of its Affiliates or Third Party Sublicensees makes any transfer of QS-21
Vaccines to Third Parties for consideration other than monetary value or as part of a multi-product transaction, such transfer will be considered a sale hereunder for Net Sales, accounting and royalty purposes. Net Sales for any such transfers will
be determined on a country by country basis and will be the average price of “arms length” sales of QS-21 Vaccines by GSK or its Affiliates or Third Party Sublicensees in such country during the royalty reporting period in which such
transfer occurs or, if no such “arms length” sales occurred in such country during such period, during the last period in which such “arms length” sales occurred. If no “arms length” sales have occurred in a particular
country, Net Sales for any such transfer in such country will be the average price of “arms length” sales of QS-21 Vaccines in all countries in the Territory by GSK, its Affiliates or Third Party Sublicensees. 
 If QS-21 Vaccine(s) is (are) sold as part of a Combination Vaccine (as hereinafter defined), Net Sales for purposes of determining royalties on QS-21 Vaccine(s) in the
Combination Vaccine shall be calculated by [**] of the [**] (as determined in accordance with the provisions of this Section) by the [**], where [**] is the [**] of the QS-21 Vaccine(s) [**] in the [**] and [**]) and [**] is the [**] of the [**] in
the [**] in the [**] and [**]). 
 As used herein, “Combination Vaccine” means QS-21 Vaccines formulated in combination with one or more
Other Vaccine Product(s). As used herein, “Other Vaccine Product” means a vaccine product, other than a QS-21 Vaccine, which is [**] with [**] and [**] when [**] with the [**] as [**] by [**] to [**]. 
 In the event that no such separate sales are made of the QS-21 Vaccine or Other Vaccine Product(s) in such Combination Vaccine in the relevant country during the royalty
period in question, then by [**] of the [**] (as determined in accordance with the provisions of this Section) by the [**], where [**] is the [**] of the [**] in [**] within the [**] and [**] and [**] is the [**] of the [**] in such [**] within the
[**] and [**]. 
 In the event that no such separate sales are made of the QS-21 Vaccines or any of the Other Vaccine Products in such Combination Vaccine in
the relevant countries within the same geographical region and similar economic profile during the royalty period in question, Net Sales, for the purposes of determining royalty payments, shall be calculated as [**] in [**] the [**], provided that
in the event the Parties are [**] to [**] to [**] on [**] after [**], then [**] shall be [**] for [**] to an [**] to the [**] shall be [**]. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 7 

 Confidential 
  

 1.27 “Other Overhead Costs” for purposes of determining Fully
Burdened Costs, means appropriate [**] and [**] of [**] related to QS-21 Manufacturing activities 
 1.28 [**] has the meaning
set forth in Section [**] of this Agreement. 
 1.29 “Quality Agreement” means (i) the Quality Agreement
entered into between the Parties contemporaneously with the 2006 Supply Agreement, and (ii) the Quality Agreement to be entered into between the Parties as soon as reasonably possible after the execution of this Agreement, each as may be
revised by the Parties from time to time and which form an integral part hereof. 
 1.30 “QS-21” means all
adjuvant isolated from Quillaja saponaria tree extract, or any structural equivalents thereof, manufactured by or on behalf of Customer. For purpose of clarification GSK has no obligation to Manufacture or have Manufactured any other saponin
outside the agreed Specifications for QS-21, unless otherwise agreed between the Parties. 
 1.31 “QS-21
Vaccine(s)” means, during the term of the License Agreement, the Licensed Vaccines, and after expiration of a Valid Claim of the Licensed Patent Rights covering the applicable Vaccine product, QS-21 Vaccines means any Vaccine product of GSK
or its Affiliates or Third Party Sublicensees formulated using QS-21. 
 1.32 “Regulatory Authority” means
the U.S. or foreign government agency or health authority that regulates and grants recommendations for approvals for the manufacture and sale of pharmaceutical products. 
 1.33 “Release” has the meaning set forth in Section 4.1 hereof. 
 1.34 “Specifications” means the applicable release specifications for QS-21 agreed to by the Parties and set out in
Exhibit A attached hereto and incorporated herein, as may be amended from time to time by mutual agreement of the Parties. 
 1.35 “Steering Committee” means the Steering Committee maintained in accordance with this Agreement. 
 1.36 “Sublicensee” means any Affiliate or Third Party to whom GSK grants a sublicense of any of the license rights granted to GSK pursuant to the terms and conditions of the License Agreement. 
 1.37 “Supplier” means (a) Antigenics MA, in the case where Antigenics MA is Manufacturing and supplying for GSK
hereunder, or (b) GSK, in the case where GSK is Manufacturing and supplying for Antigenics MA hereunder. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 8 

 Confidential 
  

 1.38 “Term” has the meaning set forth in Section 8.1 hereof.

 1.39 “Territory” means the world. 
 1.40 “Third Party” means any entity other than the Parties to this Agreement or their respective Affiliates. 

1.41 “Vaccine” means a preparation in finished form (not requiring any further processing or packaging prior to sale
to the end user). 
 1.42 “2006 Supply Agreement” has the meaning set forth in the second whereas clause.

 2. Steering Committee, Manufacturing Technology Transfer, Cooperation and License Rights. 
 2.1 General. The Parties acknowledge that Antigenics MA transferred the Manufacturing Technology Package to GSK in accordance with
the Manufacturing Technology Transfer Plan. Both Parties will perform their remaining respective activities under and in accordance with the Manufacturing Technology Transfer Plan in order to facilitate consistency in QS-21 Manufacturing between the
two Parties. 
 2.2 Steering Committee. 
 (a) Antigenics MA and GSK will maintain a steering committee (the “Steering Committee”) to oversee the activities to be
undertaken pursuant to this Agreement. The Steering Committee will facilitate communication between the Parties and provide a forum to review any technology transfer, supply and Manufacturing matters pertaining to QS-21. The Steering Committee shall
consist of three (3) individuals appointed by each Party or such other number of representatives the Parties may mutually agree upon and may also include additional representatives from the Parties, as mutually agreed, on an ad-hoc basis and
shall be co-chaired by GSK and Antigenics MA. The co-chairs will coordinate agendas and minute-taking for meetings of the Steering Committee. Each Party may replace its Steering Committee representatives at any time upon written notice to the other
Party provided that, the Party intending to change its representative(s) will [**] and will [**] to any [**]. The Steering Committee may establish certain ad hoc sub-committees which consider certain matters, including without limitation, one or
more sub-committees (consisting of at least one (1) individual from each Party) to address (i) technical matters in dispute that have not been resolved under the Quality Agreement and (ii) repetitive, specific cGMP issues. 

 

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 9 

 Confidential 
  

 (b) The Steering Committee shall meet (in person, or by teleconference or
videoconference as agreed by the Parties) at least [**] during the [**] and thereafter [**] (or more frequently as the Parties mutually agree is appropriate, or on such dates and at such times as the Parties shall agree. The Steering Committee
(itself or through one or more sub-committees as contemplated in Section 2.2(a) above) will, among other things: (i) oversee the disclosure of Manufacturing Improvements in accordance with this Agreement; (ii) review and manage the
Manufacturing relationship hereunder, including without limitation, review the Manufacturing requirements for QS-21 for Customer, (iii) discuss and review for Supplier’s reasonable consideration, the [**], discuss and review validation
plans for Manufacturing, QC testing and facilities, and coordinate efforts to ensure [**] between the two Parties; and (iv) address such other matters as may be agreed to between the Parties, including open matters that may exist at the level
of the sub-committees. In addition and without limiting the foregoing, the Steering Committee shall meet [**] starting [**] to discuss [**] and [**], with respect to QS-21 Manufacturing to ensure that GSK will meet the Capacity Date deadline of
[**]. In such meetings, GSK shall provide the Steering Committee with detailed summaries and updates with respect to the foregoing. All information provided to Antigenics MA pursuant to this Section shall be considered the Confidential Information
of GSK in accordance with Article 9; provided, however, that GSK grants permission to Antigenics MA to disclose such information as may be necessary or reasonably useful: (i) to comply with any applicable laws, rules, regulations, or
guidelines, including to reference and submit any such information to the FDA and other relevant Regulatory Authorities and (ii) for Antigenics MA and its Affiliates and QS-21 licensees and customers to [**] with respect to [**], and
(ii) for inclusion in the QS-21 BMF or comparable filing, subject to GSK’s confidential obligations to Third Parties. All information provided to GSK pursuant to this Section shall be considered the Confidential Information of Antigenics
MA in accordance with Article 9, provided however that Antigenics MA grants permission to GSK to disclose such information as may be necessary or reasonably useful: (i) to comply with any applicable laws, rules, regulations, or
guidelines, including to reference and submit any such information to the FDA and other relevant Regulatory Authorities, and (ii) for securing product license with respect to QS-21 Vaccines, subject to Antigenics MA’s confidential
obligations to Third Parties. For the avoidance of doubt, nothing in this subsection shall extend the limitation on Antigenics MA’s right to grant sublicenses to practice Manufacturing Improvements to Manufacture QS-21 as set forth in
Section 2.6 below. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 10 

 Confidential 
  

 (c) Subject to Section 10.1 below, the Steering Committee will operate by
consensus, and each Party will consider the other Party’s input in good faith, provided however that [**] shall [**] in [**] on the [**] with [**] with respect to [**], provided that (x) [**] shall not [**] in [**] that [**] in [**] to a
[**] or other [**], or [**] in [**] between (i) [**] and [**] (or, in the case of [**], its [**]) [**], or (ii) each [**], or [**] hereunder); and (y) without in any way limiting (x), Customer shall indemnify and hold harmless
Supplier from any liability incurred by Supplier as a result of [**]. 
 2.3 Manufacturing Technology Transfer Plan,
Manufacturing Technology Transfer Team and Manufacturing Technology Package. 
 (a) Manufacturing Technology Transfer
Plan. The Parties will use commercially reasonable efforts to update the Manufacturing Technology Transfer Plan and perform their respective activities thereunder, in an efficient and timely manner and in accordance with any schedule that may be
set forth in the Manufacturing Technology Transfer Plan. The Parties acknowledge that Antigenics MA has transferred to GSK all documents under the Manufacturing Technology Package and the Parties have completed the Phase 1 of the Manufacturing
Technology Transfer Plan in accordance with the timelines set forth in the 2006 Supply Agreement. The Parties shall use commercially reasonable efforts to complete their obligations under the Manufacturing Technology Transfer Plan. 
 (b) Establishment of Manufacturing Technology Transfer Team. Until completion of the Manufacturing Technology Transfer Plan (as
shall be amended by the Parties in accordance with this Agreement), GSK and Antigenics MA shall maintain a Manufacturing Technology Transfer Team comprised at least of four (4) representatives designated by GSK and at least four
(4) representatives designated by Antigenics MA; provided that GSK and Antigenics MA may designate an equal number of additional representatives from time to time. Either Party may change its designees to the Manufacturing Technology
Team at any time upon written notice to the other Party. Each representative shall have appropriate skills and competencies for its role on the team. 
 (c) Contact Persons. The Parties will identify contact persons to serve as the primary contacts for and day-to-day management of the disclosure of the Manufacturing Improvements under the Manufacturing
Technology Transfer Plan and this Agreement. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 11 

 Confidential 
  

 (d) Transfer of the Manufacturing Technology Package. The Parties acknowledge
that Antigenics MA has accomplished the Completion of the Transfer of the Manufacturing Technology Package and GSK has made the payment described in Sections 5.2 (a) and (b) below in accordance with the provisions of Section 5.2.

 2.4 Regulatory Cooperation. 
 (a) Access to Regulatory Documents and Communications. GSK will have the right to cross-reference Antigenics MA’s BMF, and
Antigenics MA has provided GSK with a redacted copy of such BMF. GSK shall also have the right to file or have filed its own BMF, and shall provide and hereby provides Antigenics MA (and its Third Party manufacturer, Affiliates, and QS-21 licensees
and customers) with an automatic, blanket right to cross-reference such BMF for all indications. GSK shall provide Antigenics MA with a redacted copy of any such BMF. In addition, each Party shall provide the other Party with relevant sections of
its BMF upon update, and shall maintain its BMF for a period of [**] from the Effective Date of this Agreement, unless otherwise agreed to between the Parties. In addition, GSK shall promptly cooperate with Antigenics MA and provide Antigenics MA
with any necessary additional documentation to effectuate the foregoing. In addition, each Party shall promptly send the other Party a copy of any material notices, material reports, and other material communications it has received from any
Regulatory Authority or other governmental entity concerning QS-21. Antigenics MA will discuss with GSK any material documents relating to Manufacturing matters for the QS-21 Vaccines pertaining to the QS-21 that Antigenics MA receives from, or
intends to submit to, the Regulatory Authorities in the Territory in line with Section 5.8 of the License Agreement and GSK will discuss with Antigenics MA any material documents relating to Manufacturing matters for QS-21 or QS-21 Vaccines
pertaining to the QS-21 that GSK receives from, or intends to submit to, the Regulatory Authorities in the Territory in line with Section 5.8 of the License Agreement. Upon one Party’s reasonable request, the other Party will reasonably
cooperate with the requesting Party in support of all regulatory filings involving QS-21, including participation in meetings with Regulatory Authorities as appropriate. In addition, Supplier will authorize and reasonably cooperate with Customer to
prepare any visit or inspection requested by Regulatory Authorities. 
 (b) Changes to Manufacturing Processes. Any
changes to Manufacturing processes shall be handled pursuant to the provisions of the Quality Agreement and Section 2.8 of this Agreement. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 12 

 Confidential 
  

 (c) Adverse Events Reporting. GSK shall be responsible for reporting all
safety related events from studies of QS-21 Vaccines to the appropriate Regulatory Authorities and agencies according to the applicable local regulations, including without limitation, the regulations outlined in 21 CFR 312.32 (and other applicable
international regulations). GSK and Antigenics MA shall keep each other informed of any serious adverse reactions, or other significant, unusual or unexpected safety findings related to QS-21 as provided for in Section 5.8 of the License
Agreement. 
 (d) Compliance. Notwithstanding the foregoing and for the avoidance of doubt, (i) GSK shall
comply, and shall cause its Sublicensees to comply, with the Specifications, the cGMP and all applicable federal and state laws, rules, regulations and guidelines in connection with its performance under this Agreement, the Manufacture of QS-21, and
the development and commercialization of QS-21 Vaccines; and (ii) Antigenics MA shall comply, and shall cause its Affiliates and Third Party Manufacturer (other than the contract manufacturer selected by the Steering Committee, whose compliance
shall be the joint responsibility of Antigenics MA and GSK) to comply, with the Specifications, the cGMP and other applicable federal and state laws, rules and regulations in connection with its performance under this Agreement and the Manufacture
of QS-21. Without limiting the generality of the foregoing, GSK shall use Commercially Reasonable Efforts (as such term is defined in the License Agreement) to ensure compliance with all applicable product safety, product testing, product labeling,
package marking, and product advertising laws and regulations and International Conference on Harmonisation (ICH) Guidelines. As between the Parties, GSK shall be solely responsible for diligently obtaining all required and/or necessary Regulatory
Authority authorizations and approvals to develop, Manufacture and commercialize QS-21 Vaccines hereunder and under the License Agreement. 
 (e) Product Recalls. Any products recalls will be handled pursuant to the terms of the Quality Agreement. 
 2.5 License Grant to GSK. 
 (a) Subject to the terms and conditions of this Agreement
(including without limitation, the provisions of Article 4 below and the retained rights of Antigenics MA set forth in Section 2.5(b) below), Antigenics MA hereby grants to GSK a [**], right and license (with the right to grant sublicenses to
its Affiliates and Sublicensees as defined in the License Agreement, subject to the provisions of Section 2.5(c) below) to the Manufacturing Technology for the sole purpose of Manufacturing QS-21: (i) to supply Antigenics MA (and its
Affiliates and QS-21 licensees and customers) in accordance with this Agreement, and (ii) to develop, make, have made, use, sell, offer for sale and import QS-21 Vaccines. To the extent that Antigenics MA 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 13 

 Confidential 
  

 
subcontracts or sublicenses with its Affiliates or Third Parties to Manufacture for GSK hereunder, Antigenics MA shall obtain the right under the
intellectual property rights of such Affiliate or Third Party related to the Manufacture of QS-21, with the right to grant sublicenses to GSK and its Affiliates (and such license shall be further sublicensable by GSK to its Affiliates and
Sublicensees, subject to the provisions of Section 2.5(c) below), to use any such intellectual property necessary for or actually applied to the Manufacture of QS-21 that is discovered or developed by such Affiliate or Third Party to preserve
the license granted to GSK and its Affiliates in this Section. 
 (b) Notwithstanding the provisions of Section 2.5(a)
above, Antigenics MA hereby retains the right and has the obligation to Manufacture QS-21 for GSK as set forth in Section 3.1 below, and any other parties. For the avoidance of doubt, nothing in this Section 2.5 shall be construed to
prevent Antigenics MA from Manufacturing or having Manufactured QS-21 for itself or any other parties. For the Term of this Agreement, GSK agrees to Manufacture or have Manufactured QS-21 solely in accordance with this Agreement, and for the term of
the License Agreement and thereafter to use QS-21 solely to develop, make, have made, use, sell, offer for sale and import QS-21 Vaccines. 
 (c) GSK may grant sublicenses to Sublicensees provided that: 
 (i) the Sublicensee will
practice the Manufacturing Technology only to the extent granted to GSK under this Agreement; 
 (ii) GSK and each Affiliate
Sublicensee will sign a side letter under which the Affiliate Sublicensee will agree to be bound by the terms of this Agreement; 
 (iii) GSK and each Third Party Sublicensee shall enter into a written agreement subject to, consistent with, and not to extend beyond the scope of GSK’s rights under, and the terms and conditions of, this Agreement, or provide for
Sublicensee obligations inconsistent with or less than GSK’s obligations under this Agreement, and which written agreement shall require the Third Party Sublicensee to agree to be bound by and comply with provisions that are consistent with the
provisions of this Agreement; 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 14 

 Confidential 
  

 (iv) GSK shall remain responsible for compliance by any Sublicensee receiving a
sublicense hereunder with all terms and conditions of this Agreement relevant to such Sublicensee. GSK shall promptly provide Antigenics MA with a copy of the relevant provisions of such agreement entered into with any Third Party Sublicensee
redacted as may be deemed appropriate by GSK for confidentiality or legal reason; and 
 (v) in addition and notwithstanding
the foregoing, GSK may grant sublicenses to Affiliate subsidiaries controlled by GSK without entering into a written side letter or sublicense agreement with such subsidiaries, provided that GSK shall and hereby guarantees and remains primarily
responsible for the performance of such subsidiaries in accordance with this Agreement. 
 Should this Agreement terminate for any reason, at
GSK’s request (or Antigenics MA’s election in the event this Agreement and the licenses granted to GSK hereunder are terminated by Antigenics MA for GSK’s material breach in accordance with Section 8.4(c)), and provided that
GSK’s Third Party Sublicensee continues to comply with the provisions of the written agreement to be entered into pursuant to this Section, the Third Party Sublicense shall survive, provided that Antigenics MA shall be substituted for GSK and
become the direct licensor of GSK’s Third Party Sublicensee, provided that Antigenics MA has approved or has not reasonably objected to such written agreement. However, Antigenics MA shall assume no obligations of GSK under such written
agreement, other than the obligation to grant the Manufacturing rights contemplated in this Section 2.5, unless Antigenics MA otherwise agrees. 
 2.6 License Grant to Antigenics MA. Subject to the terms and conditions of this Agreement, GSK shall grant and hereby grants to Antigenics MA and its Affiliates a [**], right and license, with the right to
grant sublicenses, to any Manufacturing Improvement (whether or not patented or patentable) to make or have made QS-21. For the avoidance of doubt, nothing in this Section 2.6 shall be construed as granting Antigenics MA any right to [**] or to
[**]. To the extent that GSK subcontracts or sublicenses with its Affiliates or Third Parties for the performance of GSK’s rights or obligations hereunder in accordance with this Agreement, GSK shall obtain the right under the intellectual
property rights of such Affiliate or Third Party related to the Manufacture of QS-21, with the right to grant sublicenses to Antigenics MA and its Affiliates (and such license shall be further sublicensable by Antigenics MA), to use any such
intellectual property necessary for or actually applied to the [**] that is discovered or developed by such Affiliate or Third Party to preserve the license granted to Antigenics MA and its Affiliates in 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 15 

 Confidential 
  

 
this Section. Notwithstanding the foregoing, Antigenics MA’s right to grant sublicenses to any Manufacturing Improvements of GSK to [**] conceived and
reduced to practice after the effective date of the Letter shall be limited to [**] of [**] provided that such [**] may in no event be a party listed on Exhibit C-1. In the event that GSK identifies a party not listed on Exhibit C-1 for whom GSK
does not want Antigenics MA to grant sublicense rights hereunder in the future, and such third party is a GSK Direct Competitor (as hereinafter defined), such party may be added to Exhibit C-1 upon mutual agreement of the Parties. In such an event,
GSK shall notify Antigenics MA and shall provide Antigenics MA with reasonable basis for identifying such party as a GSK Direct Competitor. In the event that Antigenics MA disagrees with GSK’s determination, then the matter shall be resolved in
accordance with Section 10.1. A GSK Direct Competitor shall be defined as any company active in [**] and/or [**] of [**] and/or [**]. For the avoidance of doubt, not all parties listed in Exhibit C-1 as of the effective date of the Letter were
Direct Competitors of GSK. For further clarification, for purpose of this Section the following entities are not to be regarded as a GSK Direct Competitor: (a) [**] or its [**], or (b) Third Party contract manufacturers whose primary
business is contract manufacturing, including without limitation, the parties listed on Exhibit C-2. 
 2.7 No Other
Rights. Except for the express licenses granted pursuant to this Article 2, no license, express or implied, is granted by either Party to the other Party under any intellectual property or other rights owned or controlled by such Party pursuant
to this Agreement. 
 2.8 Disclosure of Manufacturing Improvements. For the avoidance of doubt, no obligations on
either Party to disclose Manufacturing Improvements (and in the case of Antigenics MA, [**]) are implied by the license grants set forth herein, and the only Manufacturing Improvements (and in the case of Antigenics MA, [**]) disclosure obligations
under this Agreement are the specific disclosure and reporting obligations expressly set forth in this Agreement, the Quality Agreement or the Manufacturing Technology Transfer Plan. The Parties agree that each Party will promptly disclose to the
other Party those Manufacturing Improvements that are modifications, alternatives, improvements or other changes to the Manufacturing process that may reasonably affect the yield, scale, cost, purity, or efficiency of the Manufacturing process, or
the Specifications and shall cooperate with the other Party for a period not to exceed [**] from the last supply to the other Party hereunder to enable the other Party to practice such modifications, improvements or other changes in its
Manufacturing processes in accordance with such other Party’s rights under this Agreement. For the avoidance of doubt Antigenics MA shall be entitled to share Manufacturing Improvements conceived by GSK to its [**] and applicable Regulatory
Authorities, but shall not be entitled to disclose such Manufacturing Improvements to [**]. In the event that either Party requires the other Party to Manufacture a batch of QS-21 not otherwise to be produced by such Party, in furtherance of this
provision, the requesting Party agrees to purchase 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 16 

 Confidential 
  

 
such batch at a transfer price of [**] of the [**]. In addition, in the event that either Party requires the other Party to perform any analytical testing
outside of the Manufacture of QS-21 in accordance with the provisions of Article 3 in furtherance of this provision and not otherwise to be performed by such Party, the Parties shall negotiate in good faith a [**] to be paid by the requesting Party
for such services. 
 3. Manufacture and Supply Obligations. 
 3.1 Supply Obligations of Antigenics MA. The Parties acknowledge and agree that, subject to the terms and conditions contained in
the 2006 Supply Agreement, until the Manufacturing Transition Date (as defined under the 2006 Supply Agreement), GSK agreed to purchase solely from Antigenics MA or it Affiliates (or [**] or another Third Party manufacturer approved by GSK, such
approval not to be unreasonably withheld or delayed), and Antigenics MA or its Affiliates (or a Third Party manufacturer approved by GSK, such approval not to be unreasonably withheld or delayed) agreed to supply GSK and its Sublicensees with one
hundred percent (100%) of their initial requirements of QS-21 (subject to the Manufacturing Capacity) for use solely in the development, marketing and sale of QS-21 Vaccines in the Territory. However, after the effective date of the Letter, GSK
had and shall have no further obligation to purchase QS-21 from Antigenics MA (or its Affiliates or Third Party designee), and Antigenics MA (or its Affiliates or Third Party designee) shall have no further obligation to supply GSK and its
Sublicensees QS-21, subject to the remaining provisions of this Section 3.1. Subject to the terms and conditions contained in this Agreement, GSK shall purchase from Antigenics MA (or its approved Third Party manufacturer) and Antigenics MA (or
its approved Third Party manufacturer) shall supply to GSK, pre-commercial grade QS-21 in the amounts and timelines set forth on Exhibit B. 
 3.2 Supply Obligations of GSK. At and upon Antigenics MA’s election but not before the GSK Capacity Date, and subject to the terms and conditions contained in this Agreement, GSK shall supply Antigenics MA
(and Antigenics MA’s Affiliates and QS-21 licensees and customers) with up to [**] per [**] of commercial grade QS-21 for up to [**] from the [**] of [**] from Antigenics MA to GSK. GSK shall reasonably consider any request by Antigenics MA or
its Affiliates or [**] to extend the [**] supply term if such request will not unreasonably interfere with GSK’s business or QS-21 supply needs. GSK shall keep Antigenics MA informed as to its timelines for having commercial grade QS-21
Manufacturing capabilities. In the event that GSK determines that there is a possibility that it will not be able to supply QS-21 to Antigenics MA by [**], or thereafter have an inability to supply Antigenics MA with quantities requested by
Antigenics MA, GSK shall immediately notify Antigenics MA and cooperate with Antigenics MA to address such inability. For the avoidance of doubt, Antigenics MA has no obligation to purchase QS-21 from GSK. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 17 

 Confidential 
  

 3.3 Supply to GSK’s Sublicensees. Prior to supplying any Sublicensee
under the License Agreement with QS-21 supplied to GSK hereunder, GSK shall enter into a written agreement with such Sublicensee pursuant to which such Sublicensee acknowledges and agrees to be subject and subordinate to the provisions of this
Agreement (but specifically excluding the obligation of such Sublicensee to [**] from Antigenics MA or [**] to Antigenics MA, or make [**] to Antigenics MA other than the [**] set forth in Section [**]). 
 3.4 Forecasts and Purchase Orders. Customer shall issue forecasts and firm purchase orders for those amounts of QS-21 it intends to
purchase from Supplier hereunder as set forth below. For the avoidance of doubt, and subject to GSK’s obligations to purchase QS-21 in the amounts and in accordance with the timelines set forth in Exhibit B, Customer has no obligation to
purchase QS-21 from Supplier, other than those quantities for which Customer becomes bound and obligated in accordance with the remaining provisions of this Section 3.4. 
 (a) Rolling Forecasts. Commencing [**] before, and continuing for so long as, Supplier has Manufacture and supply obligations under
this Agreement and, subject to the last sentence of this Section 3.4(a), the following provisions shall apply. Not later than the first day of each calendar quarter, Customer shall provide Supplier with a rolling quarterly forecast of the
quantity of QS-21 that it expects to purchase from Supplier for the following next [**] calendar quarters, which shall be binding on Customer for hundred percent (100%) as to the first [**] quarters, be binding on Customer for between [**] and
[**] of the quantities of QS-21 forecasted for the next [**] quarters, and be non-binding on Customer as to the remaining [**)] calendar quarters. In the event that Customer does not comply with the provisions of this Section 3.4(a) and fails
or delays to provide its forecasts hereunder, then Supplier will notify Customer and Customer shall have [**] to comply with its obligations, otherwise Supplier may elect to fill the purchase order(s) to be placed in accordance with
Section 3.4(b) below for any of the quarters of the concerned forecast, but is not obligated to do so. Notwithstanding the foregoing, attached hereto as Exhibit B are GSK’s binding forecasts for QS-21 it intends to order from Antigenics MA
for the time period from Q3 2007 through Q4 2008, and with respect to orders made by GSK, this Section 3.4(a) shall only apply to amounts of QS-21 ordered by GSK in excess of those amounts set forth on Exhibit B, to the extent the Parties agree
that GSK may order excess amounts pursuant to the provisions of Exhibit B. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 18 

 Confidential 
  

 (b) Firm Purchase Orders. Not later than [**] prior to the beginning of each
[**] for which Supplier has Manufacture and supply obligations under this Agreement, Customer shall provide Supplier with a firm purchase order for the quantity of QS-21 it intends to purchase hereunder during such [**]. Each firm purchase order
shall specify the quantity of QS-21 to be ordered. Such firm purchase order commits Customer to purchase [**] of the quantity of QS-21 set forth in the purchase order during that [**]. In the event that Customer does not comply with the foregoing
provisions of this Section and delays ordering or does not submit a purchase order for a particular [**] in a given [**], then Supplier may notify Customer and Customer shall have [**] to comply with its purchase order obligations (and Supplier
shall have an additional [**] to supply Customer beyond the period specified in Section 3.4(c) below). In case of Customer’s failure to do so, Supplier is relieved of its Manufacture and supply obligations with respect to the applicable
[**] for which no purchase order was submitted. Notwithstanding the foregoing, in the event that (i) GSK fails to submit any purchase order with respect to orders of QS-21 binding on GSK as set forth on Exhibit B, Antigenics MA retains the
right to treat Exhibit B as such purchase order, and to deliver to, and charge GSK for, QS-21 as set forth therein in such [**]; (ii) Customer fails to submit any purchase order with respect to orders of QS-21 binding upon Customer as set forth
in Section 3.4 (a) (other than those set forth on Exhibit B), Supplier retains the right to treat [**] of the quantities mentioned in Customer’s forecasts for the first [**] and [**] of the quantities mentioned in Customer’s
binding forecasts for the next [**] of any relevant period as firm purchase orders. For the avoidance of doubt, in no event shall Supplier be obligated to Manufacture and supply QS-21 in excess of the Manufacturing Capacity unless otherwise agreed
in writing by Supplier. 
 (c) Delivery. Supplier shall deliver within [**] of the applicable [**] (the
“Contractual Delivery Date”), and in accordance with the Specifications, [**] of the quantity of QS-21 set forth in the applicable firm purchase order (subject to the Manufacturing Capacity) for the applicable calendar quarter. Such
QS-21 shall not [**]; provided, however, that Supplier may make delivery of any firm purchase order that is for less than the amount set forth in Customer’s binding forecast for that quarter, subject to payment by Customer of the [**] of
the [**] up to the amount set forth in the applicable binding forecast. In addition, Supplier shall have the right to reject any purchase order that is otherwise inconsistent with the requirements of this Agreement. If Supplier determines that any
firm purchase order submitted by Customer and not rejected by Supplier hereunder cannot be filled by the Contractual Delivery Date, including, without limitation, as a result of a supply failure by a Third Party manufacturer, Supplier shall notify
Customer in writing promptly upon making such determination. In such case, the Parties will work together, in good faith, to identify an appropriate resolution to the supply problem. If the Parties cannot reach an 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 19 

 Confidential 
  

 
agreement on an appropriate resolution to the problem within [**] of bringing this to the attention of the Steering Committee for resolution, then at either
Party’s written request but without prejudice to Section 3.5(d), resolution of the problem will be governed by the terms of Section 10.1 hereof. Notwithstanding the foregoing or any other provision of this Agreement, in the event GSK
orders QS-21 for any calendar quarter in an amount greater than [**]percent ([**]%) of the quantity ordered in the firm purchase order for the [**], Antigenics MA will use commercially reasonable efforts to meet the order, but shall be deemed to
have met the order if it supplies by the Contractual Delivery Date [**] percent ([**]%) of the quantities ordered in the firm purchase order for the [**]. In calculating [**] ([**]%) of the quantities ordered in firm purchase orders for the [**],
the Parties shall exclude quantities ordered in the [**] in excess of that which Antigenics MA must supply in order to have been deemed to have met the order. Although Supplier may upon request from Customer agree from time to time in its sole
discretion to deliver QS-21 in [**], any such agreement in a given instance shall in no event obligate Supplier to deliver subsequent future orders of QS-21 in any [**] but the [**]. 
 (d) Shipping. Each order of QS-21 shall be shipped F.O.B. Supplier’s facilities (U.C.C. terms) or, in the event Supplier has a
Third Party Manufacture QS-21 in accordance with this Agreement, then at Supplier’s discretion, F.O.B. the Third Party’s facilities. Shipping will be according to the purchase order and to any other specific written instructions of
Customer reasonably acceptable to Supplier or its approved Third Party manufacturer (or if no written instructions are given, by a common carrier selected by Supplier and reasonably agreeable to Customer, taking into consideration the specific
nature of QS-21). Title to and risk of loss for any order of QS-21 purchased by Customer shall pass to Customer upon the common carrier taking possession and control of the order of QS-21. Unless otherwise agreed to between the Parties, all QS-21
shall be [**] and in accordance with shipping instructions provided by Customer to Supplier from time to time. 
 (e) All
forecasts and purchase orders to be provided by Customer to Supplier hereunder may be transmitted to Supplier via email, provided that Supplier confirms receipt thereof within [**]. Such email communications to Antigenics MA shall be sent to
smonks@antigenics.com with a copy to dpetersen@antigenics.com. Such email communications to GSK shall be sent to jean.gilliard@gskbio.com with a copy to pierre.desmons@gskbio.com. In the event that Supplier does not confirm
receipt within [**], Customer shall contact Supplier to ensure that Supplier received such email, or in the alternative, Customer may provide such forecast or purchase order via the notice requirements of Section 10.12 of this Agreement.

  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 20 

 Confidential 
  

 3.5 Supply Controls. 
 (a) Orders From [**]. Unless otherwise elected by Antigenics MA, any QS-21 orders from [**] shall be through Antigenics MA.

 (b) Manufacturing Facility Locations. Supplier shall select in its sole discretion its location for QS-21
Manufacturing, subject to the other provisions of this Agreement including by out-contracting such Manufacturing to Third Party Manufacturer(s). Quality aspects will be managed by Supplier in accordance with this Agreement, cGMP, the Quality
Agreement, and the specifications agreed to between the Parties, and pursuant to guidelines and recommendations issued from time to time by the Regulatory Authorities. 
 (c) Customer [**] Procurement. Subject to the provisions of this Section 3.5(c), Antigenics MA will use commercially
reasonable efforts to assist GSK in arranging for the continuous supply of [**] to GSK directly from [**] or another [**] of Antigenics MA at [**] to those applicable to [**]. In the event that GSK [**] from another [**], it shall notify Antigenics
MA, and upon Antigenics MA’s request, GSK will use commercially reasonable efforts to [**] in [**] for [**] from such [**] at [**] to those applicable to [**]. Upon written request of Antigenics MA, GSK shall provide Antigenics MA with copies
of [**] and [**] of [**] from such [**] by or on behalf of GSK. 
 (d) Supplier Inability to Supply. Supplier shall
use commercially reasonable efforts to supply Customer with quantities of QS-21 ordered from Supplier by Customer pursuant to Article 3 above. As soon as Supplier determines it will be unable to deliver to Customer the quantities of QS-21 ordered
with respect to any particular calendar quarter, Supplier shall immediately notify Customer, and Customer shall then be released of its obligations under any binding forecasts or purchase orders with respect to such quantities of QS-21 that Supplier
is unable to fill for the time period that Supplier is unable to meet such Customer orders [**]. In the event that Customer engages a Third Party to Manufacture as a result of Supplier’s inability to supply hereunder, then Supplier will
cooperate with such Third Party in its efforts, consistent with the terms of this Agreement. 
 4. Supply Conditions. 
 4.1 Documentation with Deliveries. Supplier shall provide, or shall cause any Third Party manufacturer in accordance with this
Agreement to provide, to Customer, together with each shipment of QS-21, all documentation set forth in the Quality Agreement, documenting the quality control authorized release of such shipment in accordance with the terms and conditions of the
Quality Agreement (the “Release”). 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 21 

 Confidential 
  

 4.2 Testing and Acceptance. Customer shall have [**] after the delivery to
Customer of the order of QS-21 supplied hereunder to determine whether the QS-21 conforms to the Specifications (using the same validated test methods as the Supplier) and order quantity. Supplier shall transfer [**] and [**] to enable qualification
of [**]. Customer will be deemed to have acknowledged that an order of QS-21 conforms to the Specifications and order quantity and is accepted, unless Customer rejects the QS-21 order by giving written notice of non-conformity to Supplier within
such [**] period. If Customer determines that the QS-21 order fails to meet the Specifications, or that there is a shortage in the quantity delivered, it shall promptly so notify Supplier in writing within such [**] period. Any such notice shall
specify the reason, with supporting documentation, for the non-conformity or the details of any quantity shortage, as the case may be. In the event that Supplier agrees that an order of QS-21 is non-conforming with the Specifications or that there
was a shortage in quantity delivered, Supplier shall, at its own cost (including shipping) use commercially reasonable efforts to replace the non-conforming quantities of QS-21 or make up the shortage, as soon as reasonably possible. If Supplier
does not agree that the particular order of QS-21 fails to meet the Specifications or that it delivered a shortage of QS-21, it shall notify Customer and the Parties (through the Steering Committee) shall try to negotiate a mutually satisfactory
resolution of their differences. Should a dispute over the conformity of a QS-21 order persist beyond [**] days after Supplier’s notice to Customer of disagreement, a representative sample of the QS-21 at issue shall be submitted to an
independent testing laboratory designated by Customer and reasonably agreeable to Supplier for testing against the Specifications using the same validated test methods in use at Supplier. Both Parties shall cooperate in method transfer and supply of
reference materials to enable qualification of the independent test laboratory. The test results obtained from such laboratory shall be final and binding on the Parties. The cost of such test shall be borne by the Party whose results disagree with
those of the independent laboratory. Where the test results demonstrate that the QS-21 order fails to meet any of the Specifications, Supplier shall replace the non-conforming quantities of QS-21 at no additional cost to Customer as soon as
reasonably possible after receipt of such results. The provisions of this Section shall not apply to any QS-21 damaged or lost in transit after delivery by Supplier to the common carrier, which shall be the responsibility of Customer. 
 4.3 Sample Testing and Records. Sample testing and record retention shall be in accordance with the Quality Agreement. 

4.4 Inspections. During the term of Supplier’s Manufacture and supply obligations under this Agreement, and subject to the
last sentence of this Section 4.4, Supplier shall permit a reasonable number of Customer employees or agents (which in the case of [**], may include [**]) or an independent qualified inspector reasonably acceptable to [**] and/or its QS-21
customers and licensees as appropriate, as Customer may reasonably request from time to time, at least [**] per [**] (and more often if 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 22 

 Confidential 
  

 
there are repetitive, specific cGMP issues), access to Supplier’s QS-21 manufacturing facilities during normal business hours for the purpose of
Manufacturing and quality control compliance reviews and inspections (at each Party’s own cost and expense), subject to the remaining provisions of this Section 4.4. Customer agrees that prior to any such employee or agent visitor entering
such QS-21 manufacturing facilities, Customer will provide Supplier with (a) written notice of the visit at least [**] in advance for routine annual audits, and (b) reasonable advance notice, and in no event less then [**] notice for [**].
In addition, Customer will obtain from such employees or agents or independent inspector a binding confidentiality agreement in a form acceptable to Supplier (including an express acknowledgement that any such [**] shall not have the right to [**]
to [**], except in the case expressly provided for in Section [**]) in advance of any visit and that these audits do not take place more often than reasonably necessary. The Parties agree that Supplier may refuse access to or eject any Customer
employee or agent if Supplier reasonably believes, and can reasonably demonstrate to Customer that it has grounds for such belief, that such employee or agent is or may be a security risk to Supplier or does not meet Supplier’s safety or
security requirements. Supplier shall have no liability under this Agreement for refusing access to or ejecting such individual(s). Customer further agrees to protect, defend, indemnify, and hold harmless Supplier and its officers, directors,
employees, agents and assignees, from all demands, claims, actions, liability, loss, damage, costs and expenses including reasonable attorney’s fees, arising out of any claims for personal injury or property damage caused by a Customer employee
or agent while visiting such QS-21 manufacturing facilities. Notwithstanding the foregoing, if GSK’s request to inspect the QS-21 manufacturing facilities as contemplated hereunder conflicts with any Third Party rights to which Antigenics MA
has Manufacture or supply obligations, the Parties will work together, in good faith, to identify an appropriate resolution to the conflict. Further notwithstanding the foregoing, in the event that Antigenics MA has engaged a Third Party to
Manufacture and supply QS-21 to Antigenics MA for subsequent supply to GSK pursuant to this Agreement, Antigenics MA shall [**] with respect to such [**]. 
 4.5 Exchange of Information. The Parties shall fully cooperate to achieve acceptance of QS-21 Manufacturing facilities by Regulatory Authorities, and to exchange information about lots produced by the Parties
in accordance with this Agreement, the Quality Agreement and the Manufacturing Technology Transfer Plan. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 23 

 Confidential 
  

 5. Consideration. 
 5.1 Upfront Payment to Antigenics MA. As partial consideration for the Manufacturing Technology rights transferred to GSK pursuant
to the 2006 Supply Agreement and this Agreement, and Antigenics MA’s agreement to provide expertise in connection therewith in accordance with the 2006 Supply Agreement and this Agreement, the Parties acknowledge that GSK made a non-refundable,
non-creditable upfront payment to Antigenics MA in the amount of three million dollars (US$3,000,000) on July 12, 2006. 
 5.2 Additional Payments. As further consideration for the Manufacturing Technology rights and licenses transferred to GSK pursuant to the 2006 Supply Agreement and this Agreement, and Antigenics MA’s agreement to provide
expertise in connection therewith in accordance with the 2006 Supply Agreement and this Agreement, and as consideration for entering into the Letter and this Agreement, GSK has or shall pay Antigenics MA the following non-refundable, non-creditable
additional payments upon receipt of an invoice from Antigenics MA: 
  

			
	 Payment Trigger/Due Date
	  	Payment
Amount
	(a) For Completion of the Transfer of the Manufacturing Technology Package to GSK prior to the Effective Date of this Agreement	  	US $2,000,000
 (was paid)

		
	(b) For entering into the Letter and this Agreement (in lieu of the milestone payable under the 2006 Supply Agreement for Release of [**] Lots of QS-21 Manufactured by Antigenics MA in
accordance with the Specifications)	  	US $2,000,000
 (was paid)

		
	(c) As consideration for a substantial portion of the Manufacturing profits that the Parties anticipate would have otherwise been owing to Antigenics MA under the 2006 Supply Agreement, the
following additional payments shall be made:	  	
		
	 •     On or before December 31, 2008
	  	US $1,750,000
		
	 •     On or before [**]
	  	US $[**]
		
	 •     On or before [**]
	  	US $[**]

  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 24 

 Confidential 
  

 5.3 Manufacturing Technology Transfer Royalty. As further consideration for
the Manufacturing Technology rights transferred to GSK pursuant to the 2006 Supply Agreement and this Agreement, and Antigenics MA’s agreement to provide expertise in connection therewith in accordance with the 2006 Supply Agreement and this
Agreement, commencing with the First Commercial Sale of QS-21 Vaccines by GSK or its Affiliates or Third Party Sublicensees or distributors, GSK shall pay Antigenics MA a Manufacturing Technology transfer royalty (“Manufacturing Technology
Transfer Royalty”) of [**] percent ([**]%) of Net Sales throughout the Territory. 
 This Manufacturing Technology Transfer Royalty obligation shall
apply: (i) with respect to prophylactic QS-21 Vaccines for ten (10) years after the First Commercial Sale of the first prophylactic QS-21 Vaccine in a Major Market Country (as defined below); and (ii) with respect to therapeutic QS-21
Vaccines for ten (10) years after the First Commercial Sale of the first therapeutic QS-21 Vaccine in a Major Market Country. 
 In addition and
notwithstanding the foregoing, in no event shall the foregoing Manufacturing Technology Transfer Royalty obligation apply with respect to QS-21 Vaccines in the [**] for less than [**] years after the First Commercial Sale of the first prophylactic
or first therapeutic [**]; and in no event shall the foregoing Manufacturing Technology Transfer Royalty obligation apply with respect to QS-21 Vaccines in the [**] for less than [**] years after the First Commercial Sale of the first prophylactic
or first therapeutic [**]. 
 As used herein, “Major Market Country” means the countries of the United States, France, Germany, Italy, the
United Kingdom, Canada, Spain, Australia, Japan and, in the case of a Licensed Vaccine for the Licensed Indication of [**]. 
 The foregoing Manufacturing
Technology Transfer Royalty shall not be subject to any reductions. 
 5.4 QS-21 Supply Transfer Pricing. As
consideration for Antigenics MA agreeing to supply GSK with QS-21 under this Agreement, GSK shall pay Antigenics MA a transfer price of [**] percent ([**]%) of the Fully Burdened Costs for QS-21 delivered hereunder up to [**], and thereafter GSK
shall pay Antigenics MA a transfer price of [**] percent ([**]%) of the Fully Burdened Costs for QS-21 delivered hereunder. As consideration for GSK agreeing to supply Antigenics MA with QS-21 under this Agreement, Antigenics MA shall pay GSK a
transfer price of [**] percent ([**]%) of the Fully Burdened Costs for QS-21 delivered hereunder, provided that in the event that GSK has more than one QS-21 Manufacturing facility (itself or through a Third Party), then for purposes of determining
the Fully Burdened Costs of QS-21 Manufacturing by GSK, the Fully Burdened 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 25 

 Confidential 
  

 
Cost components shall not exceed the average of such costs among the various facilities, and provided further that in no event shall the Fully Burdened Cost
components exclusive of the Manufacturing direct labor and direct material costs exceed [**]. Supplier shall invoice Customer upon delivery to the common carrier and Customer shall pay Supplier in U.S. dollars (USD) within [**] days of the invoice
date unless rejected by Customer under Section 4.2 for each order of QS-21.  
 5.5 Customer’s Audit
Rights. At the request of Customer, upon at least [**] prior written notice to Supplier and at the expense of Customer (except as otherwise provided below), Supplier shall permit an experienced, independent certified public accountant selected
by Customer and reasonably acceptable to Supplier to inspect, during regular business hours, any such records of Supplier for the then-preceding [**] solely to the extent necessary to verify Fully Burden Costs provided that such inspection shall not
take place more often than once a year, and shall not cover such records for more than the preceding [**] and shall not cover the same records more than once unless this is reasonably necessary for confirming the accuracy of existing records.
Results of any such inspection shall be made available to both Parties. 
 6. Payments, Reports and Records. 
 6.1 First Commercial Sale. GSK shall notify Antigenics MA of the occurrence of the First Commercial Sale of each therapeutic QS-21
Vaccine and each prophylactic QS-21 Vaccine in each country within [**] days of its occurrence. 
 6.2 Payments.
Commencing with the First Commercial Sale of the first QS-21 Vaccine in any country, GSK shall furnish to Antigenics MA a written report within [**] days after [**] of each [**] showing, on a country-by-country basis: (i) Gross Sales by GSK and
its Affiliates and Third Party Sublicensees during the reporting period; (ii) the Net Sales of all such QS-21 Vaccines sold, and qualifying discounts as described in Section 1.26, listed by category of deductions; (iii) the
Manufacturing Technology Transfer Royalties payable in United States dollars which shall have accrued hereunder in respect of such sales; (iv) withholding taxes, if any, required by law to be deducted in respect of such sales, as applicable;
and (v) the exchange rates used in determining the amount of United States dollars. All Manufacturing Technology Transfer Royalty payments shown to have accrued to Antigenics MA by each report provided for under this Section shall be due and
payable on the date such report is due. If no payments are due for any reporting period hereunder, GSK shall so report. All payments to Antigenics MA under this Agreement shall be made in United States dollars by check payable to “Antigenics
Inc.” or, if requested by Antigenics MA, by wire transfer to an account designated by Antigenics MA. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 26 

 Confidential 
  

 6.3 Withholding Taxes. All royalty payments are exclusive of all federal,
state, local and foreign taxes, levies, and assessments, duties, customs and similar charges. GSK shall be responsible for any and all such applicable charges incident to the payments to Antigenics MA under this Agreement, other than taxes on
Antigenics MA’s income. When Antigenics MA has the legal obligation to collect such taxes, the appropriate amount shall be paid by GSK (by adding such amount to the payment otherwise due to Antigenics MA), unless GSK provides Antigenics MA with
a valid tax exemption certificate authorized by the appropriate taxing authority. In the event that GSK is required by applicable law to make deductions or withholdings from payments to Antigenics MA hereunder, then GSK shall pay such additional
amounts to Antigenics MA as may be necessary to assure that the actual amount received by Antigenics MA after deduction or withholding shall equal the amount that would have been received if such deduction or withholding were not required.

 6.4 Exchange Rates. If GSK (or its Affiliates or Third Party Sublicensees) receives revenues from the sale of QS-21
Vaccines in currency other than United States dollars, revenues shall be converted to United States dollars at the conversion rate for foreign currency as published in the eastern edition of The Wall Street Journal published on the last
Business Day of the applicable calendar quarter. 
 6.5 GSK’s Recordkeeping and Inspection. After the date of
First Commercial Sale of the first QS-21 Vaccine, GSK shall keep, and shall cause its Affiliates and Third Party Sublicensees to keep, for at least [**], records of all sales of QS-21 Vaccines in sufficient detail to permit Antigenics MA to confirm
the accuracy of GSK’s Manufacturing Technology Transfer Royalty payment calculations. At the request of Antigenics MA, upon at least [**] prior written notice to GSK or its Affiliates or Third Party Sublicensees and at the expense of Antigenics
MA (except as otherwise provided below), GSK or its Affiliates or Third Party Sublicensees shall permit an experienced, independent certified public accountant selected by Antigenics MA and reasonably acceptable to GSK or its Affiliates or Third
Party Sublicensees to inspect, during regular business hours, any such records of GSK or its Affiliates or Third Party Sublicensees for the then-preceding [**] solely to the extent necessary to verify such calculations provided that such inspection
shall not take place more often than once a year, and shall not cover such records for more than the preceding [**]. Results of any such inspection shall be made available to both Parties. If such inspection reveals a deficiency in the calculation
of Manufacturing Technology Transfer Royalty payments resulting in an underpayment to Antigenics MA by [**] or more, GSK shall pay all costs and expenses of such inspection. Any deficiencies found shall be payable by GSK within [**] of receipt of
invoice from Antigenics MA. If such inspection reveals an overpayment of Manufacturing Technology Transfer Royalty payments resulting in an underpayment to Antigenics MA [**] or more, 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 27 

 Confidential 
  

 
Antigenics MA shall refund to GSK any overpaid amounts within [**] after results of such inspection become available. For the avoidance of doubt, the rights
set forth in this Section 6.5 are in addition to the rights set forth in Section 5.5 of the Agreement. 
 6.6
Interest on Late Payments. Any payment not timely made shall bear interest at a rate equal to [**] 
 7. Indemnification and
Warranties.  
 7.1 Indemnification by GSK. GSK shall indemnify, defend, and hold harmless Antigenics MA and its
Affiliates and their respective directors, officers, employees, and agents, and its and their respective successors, heirs (current and former) and assigns (the “Antigenics MA Indemnitees”) from and against any and all loss,
liability, damage, cost, or expense (including reasonable legal fees and expenses of litigation) (collectively, “Liabilities”) suffered, incurred by, or imposed upon any such Antigenics MA Indemnitee, resulting from any Third Party
claims, demands, suits, actions, or judgments (collectively referred to hereafter as “Claims”) to the extent arising out of or resulting from (i) the development, pre-clinical or clinical testing, Manufacture, use, sale, offer
for sale, or importation of QS-21 Vaccines, including without limitation, the Manufacture of QS-21 for use therein, (ii) GSK’s breach of any representation, warranty or covenant of GSK hereunder, (iii) the negligence or intentional
misconduct of GSK, or (iv) the failure of QS-21 delivered by GSK hereunder to conform to the Specifications at the time of shipment hereunder, in each case except to the extent such Liability is attributable to the negligence or intentional
misconduct of any Antigenics MA Indemnitee, or in each case except for (iv above), the failure of QS-21 delivered by Antigenics MA to meet the Specifications at the time of shipment hereunder. 
 7.2 Indemnification by Antigenics MA. Antigenics MA shall indemnify, defend, and hold harmless GSK and its Affiliates and its and
their respective directors, officers, employees, and agents, and its and their respective successors, heirs (current and former) and assigns (the “GSK Indemnitees”) from and against any and all Liabilities suffered, incurred by, or
imposed upon any such GSK Indemnitee, resulting from any Third Party Claims to the extent arising out of or resulting from (i) the failure of QS-21 delivered by Antigenics MA (including by Antigenics MA through [**]) hereunder to conform to the
Specifications at the time of shipment hereunder, or (ii) Antigenics MA’s breach of any representation, warranty or covenant hereunder, or (iii) the negligence or intentional misconduct of Antigenics MA, in each case except to the
extent such Liability is attributable to the negligence or intentional misconduct of any GSK Indemnitee. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 28 

 Confidential 
  

 7.3 Conditions on Indemnification. Any Antigenics MA Indemnitee or GSK
Indemnitee (each an “Indemnitee”) intending to claim indemnification under this Article 7 shall promptly notify the other Party (the “Indemnifying Party”) of any Claim after the Indemnitee is aware thereof, setting
forth the nature of the Claim and the basis for indemnification hereunder, and the Indemnifying Party shall assume, at its sole cost and expense, the defense of the Claim with counsel mutually satisfactory to the Parties; provided, however,
that any Indemnitee shall have the right to retain its own counsel reasonably acceptable to the Indemnifying Party, at the expense of the Indemnifying Party, if representation of such Indemnitee by the counsel retained by the Indemnifying Party
would be inappropriate because of actual or potential differences in the interests of such Indemnitee and any other Party represented by such counsel. The Indemnitee shall cooperate fully with the Indemnifying Party in such defense and will permit
the Indemnifying Party to conduct and control such defense and disposition of such Claim (including all decisions relative to litigation, appeal and settlement), provided that (i) the Indemnifying Party agrees to keep the Indemnitee informed of
the progress in the defense and disposition of such Claim and to consult with the Indemnitee with regard to any proposed settlement, and (ii) the Indemnifying Party agrees not to enter into any settlement which would have a material adverse
effect on the other Party without prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed. This indemnity agreement shall not apply to amounts paid in settlement of any Liability if such settlement is
effected without the consent of the Indemnifying Party, which consent shall not be withheld unreasonably. The failure to deliver notice to the Indemnifying Party promptly after the Indemnitee receives notice of or otherwise becomes aware of any such
Claim, if prejudicial to its ability to defend such Claim, shall relieve the Indemnifying Party of any liability to the Indemnitee under this indemnity agreement. 
 7.4 Insurance. During the Term of this Agreement and for a period of [**] after the [**] of QS-21 Vaccines by GSK, its Affiliates
or Third Party Sublicensees or its or their distributors (or ten years after the last supply of QS-21 by GSK hereunder, if later), GSK shall, at its discretion, either self-insure through a GlaxoSmithKline plc program, or obtain and carry, and shall
cause its Sublicensees to obtain and carry, in full force and effect product liability insurance in amounts which are reasonable and customary in the pharmaceutical industry for similar products. GSK shall provide Antigenics MA with appropriate
certificates of insurance from time to time as requested by Antigenics MA unless GSK is self-insured. During the Term of Antigenics MA’s supply obligations under this Agreement and for a period of [**] after the [**] of QS-21 to GSK its
Affiliates or Third Party Sublicensees, Antigenics MA shall at its discretion, either self-insure through an Antigenics Inc. (parent corporation) program, or obtain and carry, and shall cause its sublicensees receiving QS-21 supplied by GSK
hereunder to obtain and carry, in full force and effect product liability insurance in amounts which are reasonable and customary in the pharmaceutical industry for similar products. Antigenics MA shall provide GSK with appropriate certificates of
insurance from time to time as requested by GSK unless Antigenics MA is self-insured. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 29 

 Confidential 
 7.5 Representation and Warranties of GSK. GSK represents, warrants, and covenants to Antigenics MA as follows: 
 (a) GSK is a corporation duly organized, validly existing and in good standing under the laws of Belgium. GSK has, and will have on all
relevant dates, all requisite corporate power to own and operate its properties and assets and to carry on its business as presently being conducted and as proposed to be conducted. GSK has, and will have on all relevant dates, all requisite legal
and corporate power to execute and deliver this Agreement, and to carry out and perform its obligations under the terms of this Agreement; 
 (b) the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by all appropriate GSK corporate action; 
 (c) the performance by GSK of any of the terms and conditions of this Agreement on its part to be performed does not and will not
constitute a breach or violation of any other agreement or understanding, written or oral, to which it is a party; 
 (d) GSK
will Manufacture, purchase and use, QS-21 and formulate, package and distribute the QS-21 Vaccines for marketing and sale in the Territory solely in accordance with this Agreement and the License Agreement, and applicable laws, rules, regulations,
and guidelines; and 
 (e) GSK shall Manufacture, or have Manufactured, QS-21 supplied to Antigenics MA (and its Affiliates
and QS-21 licensees and Customers) hereunder in conformity with the Specifications and applicable laws, rules, regulations, and guidelines. 
 7.6 Representation and Warranties of Antigenics MA. Antigenics MA represents and warrants to GSK as follows: 
 (a) Antigenics MA is a corporation duly organized, validly existing and in good standing under the laws of the Commonwealth of Massachusetts. Antigenics MA has all requisite corporate power to own and operate its
properties and assets and to carry on its business as presently being conducted and as proposed to be conducted. Antigenics MA has, and will have on all relevant dates, all requisite legal and corporate power to execute and deliver this Agreement;

  

 30 

 Confidential 
 (b) the execution and delivery of this Agreement and the performance of the transactions contemplated hereby have been duly authorized by
all appropriate Antigenics MA corporate action; 
 (c) the performance by Antigenics MA of any of the terms and conditions of
this Agreement on its part to be performed does not and will not constitute a breach or violation of any other agreement or understanding, written or oral, to which it is a party; and 
 (d) Antigenics MA shall Manufacture, or have Manufactured, QS-21 supplied to GSK hereunder in conformity with the Specifications and
applicable laws, rules, regulations, and guidelines. 
 7.7 LIMITATION OF LIABILITY. EXCEPT A) WITH RESPECT TO
LIABILITY RELATING TO THIRD PARTY CLAIMS UNDER SECTIONS 7.1 OR 7.2, B) LIABILITY FOR BREACH OF ARTICLE 9 AND C) CLAIMS FOR MISUSE, MISAPPROPRIATION OR INFRINGEMENT OF INTELLECTUAL PROPERTY, IT IS AGREED BY THE PARTIES THAT NEITHER PARTY NOR ITS
AFFILIATES SHALL BE LIABLE TO THE OTHER PARTY OR ITS AFFILIATES FOR ANY SPECIAL, CONSEQUENTIAL, INDIRECT, EXEMPLARY OR INCIDENTAL DAMAGES (INCLUDING LOST OR ANTICIPATED REVENUES (OTHER THAN REVENUES COMPRISING ROYALTIES OR OTHER PAYMENTS TO BE
EARNED AND PAID TO A PARTY BY THE OTHER PARTY UNDER THIS AGREEMENT) OR PROFITS RELATING TO THE SAME), ARISING FROM ANY CLAIM RELATING TO THIS AGREEMENT, WHETHER SUCH CLAIM IS BASED ON CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EVEN IF AN
AUTHORIZED REPRESENTATIVE OF SUCH PARTY IS ADVISED OF THE POSSIBILITY OR LIKELIHOOD OF SAME. 
 7.8 DISCLAIMER OF
WARRANTY. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN SECTION 7.6 HEREOF, ANTIGENICS MA MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTY OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE QS-21 MANUFACTURED AND SUPPLIED HEREUNDER,
INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT OF ANY THIRD PARTY PATENTS OR PROPRIETARY RIGHTS. ALL UNIFORM COMMERCIAL CODE WARRANTIES AND UNITED NATIONS CONVENTION ON THE
INTERNATIONAL SALE OF GOODS WARRANTIES ARE EXPRESSLY DISCLAIMED BY ANTIGENICS MA. 
 8. Term and Termination.  
 8.1 Term. Unless otherwise terminated pursuant to the terms hereof or by separate written agreement between the Parties, the term
of this Agreement (the “Term”) shall begin on the Effective Date and shall remain in full force and effect until the later of (a) each Supplier’s Manufacture and Supply obligations hereunder, or (b) expiration of the
royalty obligations provided under 

  

 31 

 Confidential 
  

 
Section 5.3 above. After expiration of the royalty obligations provided under Section 5.3 above, GSK shall have a [**] license under the
Manufacturing Technology to Manufacture QS-21 for use in any QS-21 Vaccines [**] under this Agreement, unless earlier terminated in accordance with Section 8.2 below. 
 8.2 Material Breach. If either Party materially breaches any obligation, representation or warranty contained in this Agreement,
the other Party shall be entitled to give to the Party in default written notice specifying the nature of the default and requiring it to cure such default. If such default is not cured within [**] days for payments or [**] days after the receipt of
such notice, the notifying Party shall be entitled, without prejudice to any of its other rights conferred on it by this Agreement and in addition to any other remedies available to it by law or in equity, to terminate this Agreement effective upon
written notice to the other Party. The right of a Party to terminate this Agreement, as hereinabove provided, shall not be affected in any way by its waiver or failure to take action with respect to any previous default. For the purposes of this
Section, a material breach of the [**] by one Party shall be deemed a material breach and default of this Agreement by such Party, and shall entitle the other Party to give notice of default under this Section. In addition, Antigenics MA shall have
the right to terminate this Agreement and/or [**] immediately upon written notice to GSK in the event that GSK or its Affiliates challenge, or direct or assist a Third Party to challenge, the validity, patentability or enforceability of, or
otherwise oppose any, Licensed Patent Rights (as defined in the License Agreement) or the Manufacturing Technology. 
 8.3
Termination Or Continuation for Bankruptcy of Either Party. 
 (a) Either Party may terminate this Agreement if, at any
time, the other Party shall file in any court or agency pursuant to any statute or regulation of (the United States or of) any (individual) state or (foreign) country, a petition in bankruptcy or insolvency or for reorganisation or for an
arrangement or for the appointment of a receiver or trustee of the party or of its assets, or if the other Party proposes a written agreement of composition or extension of its debts, or if the other Party shall be served with an involuntary
petition against it, filed in any insolvency proceeding, and such petition shall not be dismissed [**] after the filing thereof, or if the other Party shall propose or be a party to any dissolution or liquidation, or if the other Party shall make an
assignment for the benefit of creditors. 
 (b) All rights and licenses granted under or pursuant to this Agreement by each
Party are, and shall otherwise be deemed to be, for purposes of Article 365(n) of the U.S. Bankruptcy Code, licenses of rights to “intellectual property” as defined under Article 101 of the U.S. Bankruptcy Code so long as such rights do
not conflict with any of the terms of this Agreement. The Parties further agree that, in the event of the commencement of a bankruptcy proceeding by or against either Party under the 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 32 

 Confidential 
  

 
U.S. Bankruptcy Code, the other Party shall be entitled to a complete duplicate of (or complete access to, as appropriate) the Manufacturing Technology or
Manufacturing Improvements (as the case may be) and any such intellectual property and all embodiments of intellectual property consistent with Article 365(n) of the U.S. Bankruptcy Code, and same, if not already in its possession, shall be promptly
delivered to it (a) upon any such commencement of a bankruptcy proceeding upon its written request therefore, unless the Party subject to the bankruptcy proceeding elects to continue to perform all of its obligations under this Agreement or
(b) if not delivered under (a) above, upon the rejection of this Agreement by or on behalf of the Party subject to the bankruptcy proceeding upon written request therefore by the other Party. All such Manufacturing Technology and/or
Manufacturing Improvements and intellectual property so delivered shall remain subject to the use and confidentiality restrictions set forth in Article 9 of this Agreement and Article 9 of the [**].
 8.4 Effects of Termination. 
 (a) Orders in Progress. In the event of expiration of this Agreement, Supplier shall at Customer’s request or otherwise at its election, fill any purchase orders for QS-21 that were made by Customer and
accepted by Supplier prior to such date, and Customer shall pay Supplier for any QS-21 supplied by Supplier hereunder. In addition, in the event of early termination of this Agreement, Supplier retains the right but not the obligation to fill any
purchase orders for QS-21 that were made by Customer and accepted by Supplier prior to such date, and Customer shall pay Supplier for any QS-21 supplied by Supplier hereunder. In either such an event, and in addition to the provisions set forth in
Section 8.4(b) and (c) below, the provisions of Sections 3.4 (c) and (d) shall remain in full force and effect until the Parties have fulfilled their respective obligations with respect to such orders. 
 (b) Termination or expiration of this Agreement, for any reason, shall not deprive or relieve either Party hereto, of any right, remedy,
or obligation accrued hereunder prior to termination or expiration, and shall not effect any other rights accrued in any way under separate agreements between the Parties. 
 (c) The provisions of Articles 6 (with respect to outstanding payment obligations), 7, and 9, and Sections 2.6, 4.1 and 4.2 (with respect
to deliveries made prior to the date of expiration or termination or thereafter in accordance with Section 8.4(a) above) 4.3, 5.2, 5.3 (with respect to Net Sales of QS-21 Vaccines made prior to the date of expiration), 5.4 (with respect to
deliveries made prior to the date of expiration or termination or thereafter in accordance with Section 8.4(a) above), 5.5, 8.1, 8.4, 10.1, 10.5, 10.6 (for so long as payment obligations survive the termination or expiration of this Agreement),
10.8, 10.11, and 10.12 shall survive expiration or termination of this Agreement for any reason. In addition, the provisions of Sections 2.5, 5.3 and Article 6 (with respect to payment obligations under Section 5.3) shall survive termination of
this Agreement for any reason, 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 33 

 Confidential 
  

 
other than termination by Antigenics MA for GSK’s material breach, unless Antigenics MA elects otherwise in the case of such material breach.
Furthermore, in the event this Agreement is terminated by [**] under Section 8.2 for material breach of the [**] (as agreed to by the [**] or finally resolved in accordance with the Dispute Resolution provisions of Section 10.1 of this
Agreement), and, prior to such termination, [**] covered by a [**] (as defined in the License Agreement of a [**] of the [**] into the [**] of QS-21 at the request of the [**] that results in a [**] in the [**] of greater than [**] then the [**] to
the [**] by the [**] under Section [**] above (as applicable) shall (a) [**] be [**] a [**] at a [**], and the Parties shall [**] a [**] as [**] for [**] (which [**] shall [**] a [**] of the [**] in the [**]), and (b) [**] with respect to
any [**] not covered by a [**]. 
 9. Confidentiality. 
 9.1 “Confidential Information” shall mean any technical, scientific or business information furnished by or on behalf of
one Party or its Affiliates (the “Disclosing Party”) to the other Party or its Affiliates (the “Receiving Party”) in connection with this Agreement, the License Agreement, the 1992 Agreement, or the 2006 Supply
Agreement, or the activities contemplated hereunder and thereunder, regardless of whether such information is specifically designated as confidential and regardless of whether such information is in oral, written, electronic or other form. The terms
of this Agreement shall be considered Confidential Information of both Parties, subject to the provisions of this Article 9 and Section 10.6. Confidential Information shall not include information that: 
 (a) is generally available in the public domain or thereafter becomes available to the public through no act of the Receiving Party; or

 (b) was independently known to the Receiving Party prior to receipt thereof or was discovered independently by an employee
of the Receiving Party who had no access to the information supplied by or on behalf of the Disclosing Party; or 
 (c) was
made available to the Receiving Party as a matter of lawful right by a Third Party who had no obligations of confidentiality to the Disclosing Party. 
 9.2 Obligations. The Receiving Party agrees that it shall not, without the prior written consent of the Disclosing Party, directly or indirectly: 
 (a) make any use, including but not limited to any research, commercial or potentially commercial use thereof, of any portion of the
Confidential Information of the Disclosing Party for purposes other than those set forth in this Agreement; or 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 34 

 Confidential 
 (b) duplicate, disseminate, disclose or transfer any portion of the Confidential Information to any person, except that the Receiving
Party may disclose or permit the disclosure of Confidential Information to its Affiliates, licensees and sublicensees and its and their respective directors, officers, employees, consultants, and advisors, and investors and potential investors in
connection with a general financing transaction, and, (i) in the case of GSK, to Third Party contract manufacturers (solely for the purpose of supplying GSK) as may be useful or necessary to Manufacture for GSK as contemplated in this
Agreement, and (ii) in the case of Antigenics MA, to Third Party contract manufacturers as may be useful or necessary to Manufacture for Antigenics MA as contemplated in this Agreement, in any case, who have an ethical or fiduciary duty to the
Receiving Party or are otherwise obligated to maintain the confidential nature of such Confidential Information and who need to know such Confidential Information for the purposes set forth in this Agreement, or for other legitimate business
purposes; 
 Notwithstanding the above, the Receiving Party may disclose Confidential Information of the Disclosing Party when
required by applicable laws or government rules or regulations (including without limitation, applicable securities regulations), provided that to the extent reasonably possible, the Receiving Party provides reasonable prior written notice of such
disclosure to the Disclosing Party and takes reasonable efforts to avoid and/or minimize the extent of disclosure. 
 9.3 Upon
expiration or termination of this Agreement and upon request of the Disclosing Party, all copies of any Disclosing Party’s Confidential Information (other than the Manufacturing Technology in the case of expiration) shall be returned to the
Disclosing Party, except that each Receiving Party may retain one (1) copy of the Confidential Information received hereunder in the possession of its legal counsel, solely for monitoring its obligations under this Agreement. 
 9.4 No option, license, or conveyance of such rights, express or implied, is granted to the Receiving Party in connection with any
Confidential Information disclosed by the Disclosing Party, except for the express licenses granted in Article 2. If any such rights are to be granted to the Receiving Party, such grant shall be expressly set forth in a separate written instrument.

 10. Miscellaneous. 
 10.1 Dispute Resolution. Except for the right of any Party to apply to a court of competent jurisdiction for a temporary restraining order, a preliminary injunction or other equitable relief to preserve the
status quo or prevent irreparable harm, any dispute, other than disputes regarding the construction, validity or enforcement of patents, arising between the Parties relating to, arising out of or in any way connected with this Agreement or any term
or condition hereof, or the performance by either Party of its obligations hereunder, whether before or after termination of this Agreement, shall be resolved as follows: 
 (a) If the dispute cannot be resolved by the Parties through their duly authorized representatives (or the Steering Committee, if
applicable) within [**], the Chief Executive Officer of GSK (or his designee) and the Chief Executive Office of Antigenics, Inc., a Delaware corporation, the parent corporation of Antigenics MA (or his designee) shall meet in person at a mutually
acceptable time and location or by means of telephone or video conference within [**] of the matter being referred to them. 
  

 35 

 Confidential 
  

 (b) If the Chief Executive Officer of GSK (or his designee) and the Chief Executive
Officer of Antigenics, Inc. (or his designee) fail to first meet within [**] of the matter being referred to them, or if the dispute can not be resolved by the Chief Executive Officer of GSK (or his designee) and the Chief Executive Officer of
Antigenics, Inc. (or his designee) within [**] of the matter being referred to them, then either Party may bring such matter in a federal or state court in the State of Delaware to whose exclusive jurisdiction both Parties hereto consent.

 (c) Notwithstanding the foregoing, in the event there is a disagreement between the Parties as to whether the [**] complies
with [**] under applicable [**] and [**] from [**] or other [**], such dispute shall be resolved by an independent panel of experts (the “[**] Panel”). The [**] Panel shall be composed of one (1) member if the Parties can agree on the
sole member within [**]. Otherwise, it shall be composed of one (1) member appointed by Antigenics MA, one (1) member appointed by GSK and a third member appointed by the agreement of first two (2) members. In order to be eligible for
appointment to the [**] Panel, a person must be independent in all respects from both Antigenics MA and GSK and have the [**]. The Parties shall identify their respective appointees within [**] following notice by one Party to the other of a [**]
dispute. The first two (2) members so appointed will have an additional [**] to choose the third member. Antigenics MA and GSK shall share equally any cost involved in the engagement and services of such third member. The [**] Panel shall
determine whether, in light of all circumstances, including without limitation, [**], the [**] complies with the above referred [**]. Notwithstanding the foregoing, the Parties may, by agreement, identify a more specific or relevant [**] for the
[**] Panel to consider in resolving a particular dispute. The [**] Panel shall make its determination as soon as reasonably possible, but no later than [**] after referral of the dispute to the [**] Panel by the Parties. Decisions of the [**] Panel
shall be made by [**] vote of the members and shall be announced, with such reasoning as the [**] Panel, in its sole discretion, shall determine to be appropriate, in a document delivered on the same date to both Parties. 
 10.2 No Partnership. Nothing in this Agreement is intended or shall be deemed to constitute a partnership, distributorship, agency,
employer-employee or joint venture relationship between the Parties. No Party shall incur any debts or make any commitments for the other, except to the extent, if at all, specifically provided herein. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 36 

 Confidential 
  

 10.3 Assignments. This Agreement may not be assigned or otherwise transferred
by either Party without the prior written consent of the other Party, which consent shall not be unreasonably withheld or delayed; provided, however, that, [**] may, without such consent, assign this Agreement and any of its right or
obligations hereunder to its Affiliates or in connection with the transfer or sale of all or substantially all of the portion of its business to which this Agreement relates, or in the event of its merger or consolidation or reorganization or change
in control; provided, further, that the assigning Party shall deliver written notice of any such permitted assignment to the other Party. Notwithstanding the foregoing, in the event that [**] assigns this Agreement to a [**] (as defined in
Section [**]) without the prior written consent of [**], then (i) the license granted to [**] pursuant to Section [**] shall terminate upon [**] written notice to the [**] (provided that any sublicenses granted prior to the date of assignment
in accordance with Section [**] shall survive), (ii) [**] shall have no obligation to transfer any Confidential Information of [**] to such [**] unless [**] would have had a right under this Agreement to transfer such information to said [**]
prior to the date of the assignment, (iii) [**] shall in no event have an obligation to disclose any [**] to the [**] and (iv) at [**] discretion, inspections referred to in Section 4.4 shall be conducted by an independent qualified
inspector reasonably acceptable to the [**] rather than by the [**] itself. This Agreement shall be binding upon and inure to the benefit of the successors and permitted assigns of the Parties and the name of a Party appearing herein shall be deemed
to include the names of such Party’s successors and permitted assigns to the extent necessary to carry out the intent of this Agreement. Any attempted assignment not in accordance with this Section 10.3 shall be void. 
 10.4 Further Actions. Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other
acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 10.5 No Name
or Trademark Rights. Except as otherwise expressly provided herein, or expressly set forth in the License Agreement, no right, express or implied, is granted by this Agreement to use in any manner the names “Antigenics Inc.,”
“GlaxoSmithkline plc.” or any contraction thereof or any other trade name or trademark of Antigenics MA or GSK in connection with the performance of this Agreement. In addition, GSK agrees not to use or apply for registration of any
trademarks, tradedresses or tradenames pertaining to QS-21 (as opposed to trademarks pertaining to QS-21 Vaccines) in the Territory without Antigenics MA’s prior consent, which consent shall not be unreasonably withheld where the use of such
trademarks, tradedresses or tradenames is required by applicable laws or regulations, provided that such use by GSK is consistent with both Party’s internal trademark policies. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 37 

 Confidential 
 10.6 Public Announcements. Press releases and public announcements regarding the subject matter of this Agreement shall be made in
accordance with the provisions of the License Agreement. 
 10.7 Force Majeure. If any default or delay occurs which
prevents or materially impairs a Party’s performance and is due to a cause beyond the Party’s reasonable control, including but not limited to any act of god, flood, fire, explosion, earthquake, casualty, accident, war, revolution,
terrorist acts, civil commotion, blockade or embargo, injunction, law, proclamation, order, regulation or governmental demand, or acts, omissions or delays in acting by any Regulatory Authority, the affected Party promptly shall notify the other
Party in writing of such cause and shall exercise diligent efforts to resume performance under this Agreement as soon as possible. Neither Party shall be liable to the other Party for any loss or damage due to such cause. Neither Party may terminate
this Agreement because of such default or delay, unless such event continues unabated for a period of six (6) months, in which case the Party disadvantaged by such default or delay may, at its option, terminate this Agreement upon written
notice to the other Party. 
 10.8 Entire Agreement of the Parties, Amendments. This Agreement, including the Exhibits
attached hereto which are incorporated herein, and the License Agreement, Quality Agreement, and Manufacturing Technology Transfer Plan, constitute and contain the entire understanding and agreement of the Parties and cancels and supersedes any and
all prior negotiations, correspondence, understandings and agreements, whether verbal or written, between the Parties respecting the subject matter hereof and thereof, including without limitation, the 1992 Agreement, the 2006 Supply Agreement, and
the Letter. In the event of any inconsistency between this Agreement and the Quality Agreement or the Manufacturing Technology Transfer Plan, the provisions of the Quality Agreement or the Manufacturing Technology Transfer Plan shall prevail. In
addition and for the avoidance of doubt, the Parties hereby agree that the 1992 Agreement was terminated and fully superseded by the 2006 Supply Agreement and the License Agreement as of the effective dates of the 2006 Supply Agreement and the
License Agreement, and the 2006 Supply Agreement and the Letter are terminated and fully superseded by this Agreement as of the Effective Date of this Agreement. Notwithstanding any provision to the contrary in the 2006 Agreement, no provision
contained in that agreement shall survive termination thereof. Notwithstanding the foregoing, (a) each Party hereby agrees that all actions, suits, damages, or claims which either of them may have against the other arising under the terms of
the 1992 Agreement , by reason of any breach of the 1992 Agreement arising out of any act or failure to act prior to the effective date of the 2006 Supply Agreement, was waived or released thereby, and (b) each Party hereby agrees that all
actions, suits, damages, or claims which either of them may have against the other arising under the terms of the 2006 Supply Agreement or the Letter by reason of any breach of the 2006 Supply Agreement or the Letter arising out of any act or
failure to act prior to the Effective Date of this Agreement shall survive and be enforceable under this Agreement. No other waiver, modification or amendment of any provision of this Agreement shall be valid or effective unless made in writing and
signed by a duly authorized officer of each of the Parties. The foregoing provisions of this Section 10.8 is subject to, and in no way diminishes, the rights of the Parties under Section [**] of the License Agreement with respect to the [**]
(as defined in the License Agreement). 
  

 38 

 Confidential 
  

 10.9 Severability. If any provision of this Agreement, or part thereof, is
found by a proper authority to be unenforceable, that provision, or part thereof, shall be stricken and the remainder of this Agreement will continue in full force and effect; provided, however, that the Parties shall renegotiate an
acceptable replacement provision so as to accomplish, as nearly as possible, the original intent of the Parties. 
 10.10
Captions. The captions to this Agreement are for convenience only, and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement. 
 10.11 Applicable Law; Governing Language. This Agreement shall be governed and construed in accordance with the laws of the State
of Delaware, without regard to conflicts of laws principles. This Agreement has been prepared in the English language and the English language shall control its interpretation. All consents, notices, reports and other written documents to be
delivered or provided by a Party under this Agreement shall be in the English language, and in the event of any conflict between the provisions of any document and the English language translation thereof, the terms of the English language
translation shall control. 
 10.12 Notices and Deliveries. Any notice or other communication required or permitted
hereunder shall be in writing and shall be deemed given (a) when delivered personally, (b) three (3) Business Days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or (c) one
(1) day after deposit with a commercial express courier specifying next day delivery, with written verification or receipt, as follows: 
  

			
	If to Antigenics MA, to:	  	Antigenics Inc.
		  	3 Forbes Road
		  	Lexington MA 02421 U.S.A.
		  	Attention: Vice President, Business Development
		  	
	 with copy to:
	  	Antigenics Inc.
		  	3 Forbes Road
		  	Lexington MA 02421 U.S.A.
		  	Attention: Legal Department
		
	 If to GSK, to:
	  	GlaxoSmithKline Biologicals SA
		  	89 rue de l’Institut
		  	B-1330 Rixensart, BELGIUM
		  	Attention: President and General Manager

  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 39 

 Confidential 
  

			
		
	 with a copy to:
	  	GlaxoSmithKline Biologicals SA
		  	89 rue de l’Institut
		  	B-1330 Rixensart, BELGIUM
		  	Attention: Legal Department

 However, all invoices shall be sent by Antigenics MA to GSK’s Licensing Manager, Account
Department, GlaxoSmithKline Biologicals SA, 89 rue de l’Institut, B-1330 Rixensart, Belgium or at such other address GSK may later designate in writing. 
 10.13 Counterparts. This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. 
 [The remainder of this page is intentionally left blank.]

  

 40 

 Confidential 
 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be signed by their respective corporate officers, duly authorized as of the day and
year first above written. 
 Antigenics Inc., a Massachusetts corporation and wholly owned subsidiary of Antigenics Inc., a Delaware corporation

  

			
	By:	 	 /s/ Garo Armen

	Name:	 	 Garo Armen

	Title:	 	 CEO

	
	GlaxoSmithKline Biologicals SA
		
	By:	 	 /s/ J. Stephenne

	Name:	 	 J. Stephenne

	Title:	 	 President & General Manager GSK Biologics

  

 41 

 Confidential 
  

 Exhibit A 
 Specifications 
 [**] Specifications* 
 QS-21 shall be produced and released according to Manufacturing methods and applicable [**] 
 The release criteria and specifications are set in the Quality Agreement. 
 [**] Specifications* 
 QS-21 shall be produced and released in [**], in accordance with [**] methods
of Manufacturing [**]. 
 The release criteria and specifications are set in the current Quality Agreement. 
 *The Parties agree that the [**] Specifications shall apply to Antigenics MA’s supply obligations hereunder and the [**] Specifications shall apply
to GSK’s supply obligations hereunder. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 i 

 Confidential 
  

 Exhibit B 
 GSK’s QS-21 Forecasts 
 Q3 2007: [**] (binding on GSK) 
 Q4 2007: [**] (binding on GSK) 
 Q1 2008:
[**] (binding on GSK) 
 Q2 2008: [**] (binding on GSK) 
 Q3 2008: [**] (binding on GSK) 
 Q4 2008: [**] (binding on GSK) 
 GSK may request additional quantities from Antigenics MA in 2009, subject to the below provisions*. 
 *Antigenics MA will inform GSK by [**] if Antigenics MA can provide additional quantities of QS-21 after Q4 2008 (but in no event more than [**] per
quarter unless otherwise agreed by Antigenics). In any such event, GSK would be obligated to provide forecasts in accordance with Section 3.4 of this Agreement for any additional quantities within Antigenics MA’s capacity. 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 i 

 Confidential 
  

 Exhibit C-1 
 [**] 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 i 

 Confidential 
  

 Exhibit C-2 
 [**] 
  

	 	

 [**] = Portions of this exhibit have been omitted pursuant to a
confidential treatment request. An unpredicted version of this exhibit has been filed separately with the Commission. 
  

 ii

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00158-of-00352.parquet"}]]